{"title":"SARMs Sets","description":"\u003ch2\u003eSARMs UK – Selective Androgen Receptor Modulators \u0026amp; Research Compounds\u003c\/h2\u003e\n\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eExplore the BioPlex collection of double and triple research combinations developed for structured laboratory investigation across androgen-receptor, metabolic and molecular signalling pathways. The range brings together established selective androgen receptor modulators including RAD-140 (Testolone), MK-2866 (Ostarine), LGD-4033 (Ligandrol), S-4 (Andarine), AC-262 (Accadrine), ACP-105 (Androxepen) and S-23 (Mastorin), providing researchers with access to multiple compounds within carefully organised sets.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eAlongside conventional SARMs, the collection features related research molecules including MK-677 (Ibutamoren), SR-9009 (Stenabolic), SR-9011, GW-0742 (Fitorine) and MK-777 (Acetamoren). These compounds represent different areas of experimental research, including growth-hormone-secretagogue activity, REV-ERB signalling, PPAR-associated pathways and metabolic regulation, and are not incorrectly classified as selective androgen receptor modulators.\u003c\/p\u003e\n\u003cp\u003eEach combination is organised around relevant scientific pathways, enabling comparative investigation of individual compounds while maintaining their distinct molecular classifications and research profiles. Double and triple sets cover myogenic signalling, androgen-receptor activity, metabolic pathways and growth-factor-associated research.\u003c\/p\u003e\n\u003cp\u003eBrowse the BioPlex range to compare SARM capsules and related research compounds within a dedicated UK laboratory research collection. All products are supplied exclusively for scientific, analytical and laboratory research and are not for human consumption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"z-0 flex min-h-[46px] justify-start\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv class=\"mt-3 w-full empty:hidden has-[\u0026gt;_:empty]:hidden\"\u003e\n\u003cdiv class=\"text-center\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1\"\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e","products":[{"product_id":"rad-140-lgd-4033","title":"RAD-140 + LGD-4033","description":"\u003ch2\u003eRAD-140 (Testolone) + LGD-4033 (Ligandrol) | SARMs Research UK\u003c\/h2\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eMuscle Formation Research Set\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Muscle Formation Research Set combines RAD-140 (Testolone) 50×15mg and LGD-4033 (Ligandrol) 50×15mg, two non-steroidal selective androgen receptor modulators studied for their interactions with androgen-receptor signalling and associated tissue-response pathways. The set contains one pot of each research compound, creating a structured pairing for comparative laboratory investigation of two recognised SARMs with related primary molecular targets but distinct chemical characteristics and research histories.\u003c\/p\u003e\n\u003cp\u003eRAD-140 and LGD-4033 both interact principally with the androgen receptor, but they should not be regarded as interchangeable compounds. Each has a different molecular structure, pharmacological profile and evidence base. RAD-140 has attracted research interest through receptor-binding studies, preclinical investigations of tissue-selective activity and subsequent specialised clinical research. LGD-4033 has been examined through controlled research involving pharmacokinetics, hormone-related variables, body composition and lean-tissue endpoints.\u003c\/p\u003e\n\u003cp\u003eThese differences make the combination particularly interesting from a comparative research perspective. Rather than examining a single androgen-receptor modulator in isolation, researchers can consider how two structurally different ligands targeting the same receptor system may produce different experimental observations depending on exposure, receptor expression, cellular environment and the endpoints selected for measurement.\u003c\/p\u003e\n\u003cp\u003eThe Muscle Formation Research Set name describes the principal scientific theme surrounding this pairing rather than guaranteeing a particular experimental result. Findings involving androgen-receptor modulators can vary considerably according to model selection, concentration, exposure duration, tissue type and methodology. \u003c\/p\u003e\n\u003cp\u003eBy presenting RAD-140 and LGD-4033 together while retaining their individual identities, BioPlex provides a convenient research format for investigating similarities and differences between two recognised selective androgen receptor modulators. Both compounds are supplied as separately identified 50×15mg capsule products intended strictly for laboratory, analytical and educational research.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2\u003eHow RAD-140 and LGD-4033 Work Together\u003c\/h2\u003e\n\u003cp\u003eRAD-140 (Testolone) and LGD-4033 (Ligandrol) share the androgen receptor as their principal molecular target. The androgen receptor is a ligand-activated nuclear receptor involved in regulating androgen-responsive gene transcription. When an appropriate ligand binds to this receptor, the resulting receptor complex can undergo conformational changes, interact with cellular regulatory proteins and influence transcriptional activity within the experimental system being studied.\u003c\/p\u003e\n\u003cp\u003eThe research interest in placing RAD-140 and LGD-4033 within the same set therefore comes from examining two chemically distinct ligands operating through the same broad receptor pathway. Sharing a primary target does not mean the compounds are identical. Differences in molecular structure, receptor interaction, pharmacokinetics, metabolism, tissue exposure and interactions with cellular co-regulators can all contribute to different experimental profiles.\u003c\/p\u003e\n\u003cp\u003eRAD-140 has extensive discovery-stage and preclinical characterisation involving androgen-receptor activity and tissue-selective responses. LGD-4033 has a different evidence profile that includes controlled investigation of pharmacokinetics, endocrine markers and lean-body-mass endpoints. Examining these compounds within the same research theme allows receptor-level similarities to be considered alongside compound-specific experimental findings.\u003c\/p\u003e\n\u003cp\u003eWithin controlled laboratory research, this pairing may therefore provide a framework for investigating androgen-receptor activation, transcriptional responses, tissue-specific signalling and differences between compounds operating through related molecular mechanisms.\u003c\/p\u003e\n\u003cp\u003eImportantly, grouping RAD-140 and LGD-4033 together does not establish that their experimental effects will automatically be additive or synergistic. Equal quantities also do not necessarily result in equivalent exposure, receptor occupancy or biological activity.\u003c\/p\u003e\n\u003cp\u003eThe scientific value of this combination lies in bringing two recognised SARMs together for comparative investigation while maintaining the distinction between their individual pharmacological characteristics. Appropriate controls, validated compound identity, defined experimental conditions and predetermined endpoints remain essential when interpreting findings involving either compound independently or within combined research.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eRAD-140 (Testolone) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eRAD-140, commonly known as Testolone and also investigated under development names including Vosilasarm, is a synthetic non-steroidal selective androgen receptor modulator. It was developed as part of research investigating whether androgen-receptor signalling could be selectively modulated while producing differentiated patterns of activity across androgen-responsive tissues.\u003c\/p\u003e\n\u003cp\u003eIts principal molecular target is the androgen receptor. Following ligand binding, androgen-receptor signalling can influence transcription of androgen-responsive genes. The resulting experimental response, however, depends upon numerous variables including receptor expression, cellular environment, regulatory proteins, compound concentration, exposure duration and the particular biological model being investigated.\u003c\/p\u003e\n\u003cp\u003eEarly RAD-140 research included receptor assays and preclinical investigations examining tissue-selective anabolic-androgenic activity. These studies helped establish RAD-140 as an important experimental compound within selective androgen receptor modulator research and generated interest in its behaviour across muscle-associated, bone-associated and other androgen-responsive experimental models.\u003c\/p\u003e\n\u003cp\u003eRAD-140 subsequently progressed beyond discovery-stage investigation. Clinical research has examined the compound, under the name Vosilasarm, within a specialised androgen-receptor-positive breast-cancer setting. This provides additional human pharmacology information but should not be extrapolated directly to unrelated research questions or treated as evidence for outcomes outside the conditions investigated.\u003c\/p\u003e\n\u003cp\u003eMore recent skeletal-muscle research has also demonstrated an important principle when interpreting RAD-140: a plausible receptor mechanism does not guarantee that every experimental model will produce an anticipated tissue response. Experimental design, biological conditions, exposure and selected endpoints remain critical.\u003c\/p\u003e\n\u003cp\u003eWithin the Muscle Formation Research Set, RAD-140 provides one side of a structured androgen-receptor comparison. Its distinct molecular structure, substantial preclinical research history and developing clinical evidence make it relevant for investigating how separate non-steroidal androgen-receptor ligands can share a primary molecular target while demonstrating different experimental characteristics.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eLGD-4033 (Ligandrol) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eLGD-4033, commonly known as Ligandrol and also identified by the development code VK5211, is a synthetic non-steroidal selective androgen receptor modulator developed for research into tissue-selective androgen-receptor activity. It has become one of the better-characterised compounds within the wider SARM research field because its evidence base extends from preclinical investigation into controlled human research.\u003c\/p\u003e\n\u003cp\u003eLike RAD-140, LGD-4033 principally targets the androgen receptor. Binding can influence receptor conformation and downstream transcriptional regulation, although the resulting experimental response can vary according to receptor distribution, cellular characteristics, compound exposure, regulatory proteins and the specific endpoints selected for measurement.\u003c\/p\u003e\n\u003cp\u003eLGD-4033 is particularly notable because published controlled research has examined its pharmacokinetic and biological characteristics. A placebo-controlled study investigated LGD-4033 over a 21-day period at several experimental dose levels and evaluated pharmacokinetics alongside safety observations, hormone-related variables, lipid markers, body composition and physical-performance endpoints.\u003c\/p\u003e\n\u003cp\u003eThe investigation reported dose-related changes in lean body mass while also documenting changes across other measured variables. These findings provide useful controlled evidence concerning LGD-4033 exposure and selected lean-tissue-related endpoints. However, the relatively short duration of the research does not establish long-term outcomes or answer every question surrounding androgen-receptor modulation.\u003c\/p\u003e\n\u003cp\u003eThis distinction becomes particularly useful when LGD-4033 is considered alongside RAD-140. Although both compounds belong to the same broad SARM category and interact with the androgen receptor, their molecular structures and research histories differ.\u003c\/p\u003e\n\u003cp\u003eWithin the Muscle Formation Research Set, LGD-4033 therefore provides a complementary research profile to RAD-140. Its controlled pharmacokinetic and lean-tissue research can be considered alongside RAD-140's extensive discovery and preclinical characterisation, providing a structured framework for comparative androgen-receptor investigation without assuming that the two compounds will behave identically across different laboratory models.\u003c\/p\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e \u003c\/p\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eExplore Related Research Compounds\u003c\/strong\u003e\u003cbr\u003eContinue exploring related androgen-receptor and SARMs-category research compounds from BioPlex.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\" title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/lgd-4033-ligandrol-br-50x15mg\" title=\"LGD-4033 Ligandrol | Research SARM Capsules | BioPlex UK\"\u003eView LGD-4033 Ligandrol 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003eExplore All BioPlex SARMs Research Compounds ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/strong\u003e\u003cbr\u003eAccess BioPlex SARMs guidance, company information and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/pages\/about-bioplex\" title=\"About BioPlex Peptides UK | Research Compound Supplier\"\u003eLearn More About BioPlex Peptides ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all\" title=\"BioPlex Peptides | All Research Products\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/strong\u003e\u003cbr\u003eContinue your research with BioPlex articles covering RAD-140, LGD-4033, androgen-receptor signalling and comparative SARMs research.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-rad-140-vs-lgd-4033-androgen-receptor-research-compared\" title=\"RAD-140 vs LGD-4033 Androgen Receptor Research | BioPlex Peptides\"\u003eRead RAD-140 vs LGD-4033: Androgen-Receptor Research Compared ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/best-sarms-for-muscle-growth-top-3-research-compounds-explained-2026-guide\" title=\"RAD-140 vs LGD-4033 vs YK-11 SARMs Research | BioPlex Peptides\"\u003eRead Best SARMs for Muscle Growth: RAD-140 vs LGD-4033 vs YK-11 ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eDisclaimer\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003eFor research purposes only. Not for human consumption\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753066008960,"sku":null,"price":85.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/RAD-140_Testolone_50x15mg_LGD-4033_Ligandrol_50x15mg_ccf55c51-176c-460c-817a-b1416c882d03.png?v=1787431352"},{"product_id":"mk-2866-s-4","title":"MK-2866 + S-4","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eMK-2866 (Ostarine) + S-4 (Andarine) | SARMs Research UK\u003c\/h2\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eLean Tissue Research Set\u003c\/h2\u003e\n\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eThe BioPlex Lean Tissue Research Set combines MK-2866 (Ostarine) 50×15mg and S-4 (Andarine) 50×15mg, two non-steroidal selective androgen receptor modulators investigated for their interactions with androgen-receptor signalling and tissue-selective research pathways. The set contains one pot of each research compound, creating a paired format for comparative laboratory investigation of two recognised SARMs that share a principal receptor target while maintaining distinct chemical structures, experimental histories and research profiles.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eMK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is one of the more extensively investigated selective androgen receptor modulators. Research surrounding the compound includes androgen-receptor activity, tissue-selective signalling, lean-tissue-related measurements and other controlled biological endpoints. S-4, commonly known as Andarine, is another genuine selective androgen receptor modulator investigated within androgen-receptor and tissue-response research, although its published evidence profile differs from that of Ostarine.\u003c\/p\u003e\n\u003cp\u003eThese differences make the two compounds particularly relevant for comparative investigation. Rather than treating all compounds classified as SARMs as interchangeable, researchers can examine how structurally different ligands targeting the androgen receptor may demonstrate differing experimental characteristics according to concentration, receptor expression, tissue environment, exposure and selected endpoints.\u003c\/p\u003e\n\u003cp\u003eThe Lean Tissue Research Set name reflects an important area of selective androgen-receptor research rather than promising a particular experimental result. Findings observed with one compound or model should not automatically be transferred to another SARM or research environment.\u003c\/p\u003e\n\u003cp\u003eBy bringing MK-2866 and S-4 together while preserving their individual identities, BioPlex provides a structured research pairing for investigating two recognised androgen-receptor modulators within the same scientific framework. Both compounds are supplied as separately identified 50×15mg capsule products intended strictly for laboratory, analytical and educational research.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow MK-2866 and S-4 Work Together\u003c\/h2\u003e\n\u003cp\u003eMK-2866 (Ostarine) and S-4 (Andarine) share the androgen receptor as their principal molecular research target. The androgen receptor is a ligand-activated nuclear receptor involved in regulating androgen-responsive gene transcription. Interaction between a suitable ligand and this receptor can alter receptor conformation, interactions with regulatory proteins and subsequent transcriptional activity within the biological system being investigated.\u003c\/p\u003e\n\u003cp\u003eThe scientific rationale for placing MK-2866 and S-4 within the same research set therefore comes from examining two chemically distinct compounds operating through a related receptor pathway. Both belong to the selective androgen receptor modulator category, yet this shared classification does not mean their pharmacological or experimental characteristics are identical.\u003c\/p\u003e\n\u003cp\u003eDifferences in molecular structure can affect receptor interaction, exposure, metabolism and downstream responses. Tissue type, receptor density, co-regulatory proteins, concentration and experimental duration may also influence the observations produced by either compound. This makes comparative research particularly important when examining members of the wider SARM category.\u003c\/p\u003e\n\u003cp\u003eMK-2866 has a comparatively developed research history and provides a useful reference compound when considering selective androgen-receptor signalling. S-4 has its own experimental profile and should be interpreted according to evidence specifically associated with Andarine rather than by transferring findings from Ostarine or other SARMs.\u003c\/p\u003e\n\u003cp\u003eWithin controlled research, the pairing can therefore provide a framework for examining receptor activation, transcriptional responses, tissue-selective signalling and compound-specific differences under predefined experimental conditions.\u003c\/p\u003e\n\u003cp\u003eGrouping MK-2866 and S-4 together does not establish that their effects are additive or synergistic. Equivalent nominal quantities also do not establish equivalent receptor occupancy or biological activity. The value of the combination lies instead in comparative investigation of two distinct androgen-receptor ligands, supported by validated compound identity, suitable controls, defined concentrations and clearly established research endpoints.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eMK-2866 (Ostarine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eMK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator investigated for its interactions with androgen-receptor signalling. It is one of the most widely recognised compounds within SARM research and has a more developed evidence base than many experimental compounds marketed within the same broad category.\u003c\/p\u003e\n\u003cp\u003eIts principal molecular target is the androgen receptor. This receptor functions as a ligand-activated transcription factor capable of influencing expression of androgen-responsive genes. When MK-2866 interacts with the receptor, the resulting response can depend upon receptor distribution, cellular environment, co-regulatory proteins, compound exposure and the specific endpoint being measured.\u003c\/p\u003e\n\u003cp\u003eOstarine has been investigated across preclinical and clinical research environments involving tissue-related measurements and other biological endpoints. This broader experimental history makes MK-2866 particularly useful when researchers need a comparatively well-characterised androgen-receptor modulator against which other SARM compounds can be considered.\u003c\/p\u003e\n\u003cp\u003eHowever, the existence of a broader research record should not be interpreted as establishing every claim associated with Ostarine. Findings remain dependent upon study design, research population or model, exposure duration and measurement methodology. Observations produced under one experimental condition cannot automatically be generalised to another.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Lean Tissue Research Set, MK-2866 provides the more extensively documented component of the pairing. Its established relationship with androgen-receptor research allows it to be considered alongside the separate experimental profile of S-4 Andarine.\u003c\/p\u003e\n\u003cp\u003eBioPlex also maintains dedicated educational material covering Ostarine MK-2866, including androgen-receptor signalling, SARM selectivity, tissue-marker research and related scientific considerations, providing a wider research-information pathway for researchers examining this compound. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eS-4 (Andarine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eS-4, commonly known as Andarine, is a synthetic non-steroidal selective androgen receptor modulator investigated within research concerning androgen-receptor activation and tissue-selective signalling. Its classification as a SARM is based on its relationship with androgen-receptor pharmacology, distinguishing it from compounds sometimes grouped commercially alongside SARMs despite operating through completely different molecular pathways.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor functions as a ligand-activated nuclear transcription factor. When a suitable compound interacts with the receptor, changes in receptor conformation and co-regulatory interactions can influence expression of androgen-responsive genes. S-4 has been investigated within this wider pharmacological framework as researchers have explored selective androgen-receptor modulation and differences in signalling across experimental tissue models.\u003c\/p\u003e\n\u003cp\u003eS-4 should nevertheless be considered independently from MK-2866. Although both compounds belong to the same broad pharmacological category, their molecular structures, experimental histories and available evidence are not identical. Findings obtained with Ostarine therefore should not automatically be attributed to Andarine.\u003c\/p\u003e\n\u003cp\u003eThis distinction is particularly important when comparing selective androgen receptor modulators. Classification identifies a shared receptor pathway but does not establish equivalent potency, efficacy, pharmacokinetics, tissue selectivity or downstream biological responses. These characteristics require compound-specific investigation under appropriately controlled experimental conditions.\u003c\/p\u003e\n\u003cp\u003eWithin the Lean Tissue Research Set, S-4 provides a second androgen-receptor ligand against which the more extensively researched MK-2866 can be considered. This creates a structured framework for investigating similarities and differences between two recognised selective androgen receptor modulators while maintaining clear separation between their individual evidence profiles.\u003c\/p\u003e\n\u003cp\u003eBioPlex's wider SARMs research material also distinguishes compounds such as Ostarine and Andarine from other research chemicals according to their molecular classification and androgen-receptor pathway, helping support accurate interpretation of the SARMs research category. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and SARMs-category research compounds from BioPlex.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-2688-ostarine-br-50x15mg\" title=\"MK-2866 Ostarine | Research SARM Capsules | BioPlex UK\"\u003eView MK-2866 Ostarine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"S-4 Andarine | Research SARM Capsules | BioPlex UK\"\u003eView S-4 Andarine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Compounds ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, company information and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/pages\/about-bioplex\" title=\"About BioPlex Peptides UK | Research Compound Supplier\"\u003eLearn More About BioPlex Peptides ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all\" title=\"BioPlex Peptides | All Research Products\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering Ostarine MK-2866, selective androgen-receptor signalling and the wider SARMs research category. BioPlex's live research library includes a dedicated Ostarine MK-2866 Research Overview. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"Ostarine MK-2866 Research Overview | BioPlex Peptides\"\u003eRead the Ostarine MK-2866 Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"Legal Notice | BioPlex Peptides UK\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\"\u003eFor research purposes only. Not for human consumption\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753125515648,"sku":null,"price":86.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MK-2866_S-4.png?v=1787431877"},{"product_id":"rad-140-rad-150","title":"RAD-140 + RAD-150","description":"\u003ch2\u003eRAD-140 (Testolone) + RAD-150 (TLB-150) | SARMs Research UK\u003c\/h2\u003e\n\u003ch2\u003eAdvanced Androgen Signalling Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Advanced Androgen Signalling Research Set combines RAD-140 (Testolone) 50×15mg and RAD-150 (TLB-150) 50×15mg, bringing together two closely related selective androgen receptor modulator research compounds for comparative laboratory investigation. The set contains one pot of each compound and is particularly relevant to research examining androgen-receptor signalling, molecular modification, tissue-selective pathways and the differences that may exist between a better-characterised parent compound and a structurally related derivative.\u003c\/p\u003e\n\u003cp\u003eRAD-140 is a non-steroidal selective androgen receptor modulator with a comparatively established research history. Published investigation has examined its androgen-receptor activity, tissue-selective pharmacology and behaviour across preclinical models, with additional specialised clinical research adding to its scientific evidence base. RAD-150, also known as TLB-150 or TLB-150 Benzoate, is commonly described in the research-compound field as a modified benzoate analogue related to RAD-140. However, the direct published evidence available specifically for RAD-150 is substantially more limited. BioPlex's existing RAD-150 research material makes this distinction explicitly rather than treating evidence for RAD-140 as though it automatically applies to RAD-150. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThis relationship makes the pairing particularly useful from a comparative research perspective. Researchers can examine the established androgen-receptor framework surrounding RAD-140 while considering how structural modification may affect molecular identity, analytical characteristics and hypotheses concerning compound behaviour.\u003c\/p\u003e\n\u003cp\u003eThe Advanced Androgen Signalling Research Set name reflects this shared scientific pathway rather than suggesting a predetermined experimental result. Similarity between two compounds does not establish identical pharmacology.\u003c\/p\u003e\n\u003cp\u003eBy presenting RAD-140 and RAD-150 together while preserving the distinction between their evidence bases, BioPlex provides a structured research pairing for examining two related compounds within androgen-receptor and SARM research.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow RAD-140 and RAD-150 Work Together\u003c\/h2\u003e\n\u003cp\u003eRAD-140 (Testolone) and RAD-150 (TLB-150) are closely connected within selective androgen receptor modulator research because RAD-150 is commonly described as a structurally modified, benzoate-related analogue of RAD-140. This makes the combination different from a pairing of two unrelated SARMs. Instead, it creates an opportunity to investigate a better-characterised parent research compound alongside a closely related derivative within the same androgen-receptor research framework.\u003c\/p\u003e\n\u003cp\u003eRAD-140 is studied principally through the androgen receptor, a ligand-activated nuclear receptor involved in regulation of androgen-responsive gene transcription. Ligand interaction can initiate changes in receptor conformation and subsequent processes involving co-regulatory proteins, nuclear signalling and transcriptional activity. RAD-140 research has provided a comparatively substantial foundation for investigating these processes.\u003c\/p\u003e\n\u003cp\u003eRAD-150 is discussed through the same broad androgen-receptor research area because of its structural relationship to RAD-140. However, this relationship must be interpreted carefully. Direct published pharmacological evidence specifically characterising RAD-150 remains limited compared with RAD-140. Claims that RAD-150 necessarily produces extended activity, different potency or superior experimental outcomes should therefore not be presented as established findings. BioPlex's RAD-150 research overview specifically identifies this evidence gap. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThe scientific interest in placing these compounds together consequently lies in comparative investigation. Structural modification may affect molecular weight, analytical identity, solubility, stability, exposure or other experimental characteristics, but each variable requires appropriate measurement rather than assumption.\u003c\/p\u003e\n\u003cp\u003eGrouping RAD-140 and RAD-150 together also does not establish additive or synergistic activity. Instead, the pairing provides a controlled framework for examining molecular relationship, androgen-receptor signalling, compound identity and potentially differing experimental behaviour.\u003c\/p\u003e\n\u003cp\u003eThis makes careful analytical verification particularly important. Appropriate controls and compound-specific identification allow observations involving RAD-150 to remain separate from established RAD-140 evidence while still permitting meaningful comparison between the related molecules.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eRAD-140 (Testolone) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eRAD-140, commonly known as Testolone and investigated clinically under the name Vosilasarm, is a synthetic non-steroidal selective androgen receptor modulator. It was developed within research exploring whether androgen-receptor signalling could be modulated selectively across different tissue environments, creating an important experimental compound for investigating receptor pharmacology, transcriptional responses and tissue-associated signalling.\u003c\/p\u003e\n\u003cp\u003eThe principal molecular target of RAD-140 is the androgen receptor. This receptor belongs to the nuclear-receptor family and functions as a ligand-responsive regulator of gene transcription. Following interaction with a suitable ligand, changes in receptor conformation and associated cellular processes can influence androgen-responsive transcription. The resulting biological observations depend upon the experimental system, receptor expression, co-regulator availability, concentration, exposure and selected endpoints.\u003c\/p\u003e\n\u003cp\u003eRAD-140 has considerably more direct published research than RAD-150. Its research history includes receptor-focused investigation and preclinical studies examining tissue-selective activity. It has also progressed into specialised clinical research, providing a broader evidence base than is available for many experimental SARMs.\u003c\/p\u003e\n\u003cp\u003eThat evidence remains important when RAD-140 is paired with a structurally related compound. Researchers have a comparatively established scientific framework against which analytical and experimental observations concerning RAD-150 can be considered.\u003c\/p\u003e\n\u003cp\u003eRAD-140 should nevertheless not be treated as a universal proxy for RAD-150. A structural relationship does not establish identical molecular behaviour, exposure or biological response. Each compound requires its own identification and experimental interpretation.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Androgen Signalling Research Set, RAD-140 therefore serves as the better-characterised component of the pairing. Its established association with androgen-receptor research provides a useful reference point for examining how a structurally related derivative may compare while avoiding the assumption that evidence from the parent compound automatically proves the characteristics of RAD-150.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eRAD-150 (TLB-150) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eRAD-150, commonly identified as TLB-150 or TLB-150 Benzoate, is a non-peptide research compound associated with the selective androgen receptor modulator category. It is commonly described as a modified benzoate-related analogue of RAD-140 Testolone, which explains why RAD-150 and RAD-140 frequently appear together in research-compound comparisons and analytical discussions.\u003c\/p\u003e\n\u003cp\u003eThis relationship is scientifically interesting but requires careful interpretation. RAD-150 does not currently possess the same depth of direct published pharmacological evidence as RAD-140. Much of the discussion surrounding RAD-150 derives from its structural relationship to the better-characterised RAD-140 molecule rather than from a large body of independent experimental studies. BioPlex's existing RAD-150 Research Overview explicitly highlights this distinction. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eRAD-150 is generally discussed within androgen-receptor signalling research. This can include investigation of receptor interaction, tissue-selective signalling models, transcriptional pathways and analytical comparison with related selective androgen receptor modulators. However, characteristics proposed online for RAD-150 should not be considered scientifically established merely because related effects or mechanisms have been investigated for RAD-140.\u003c\/p\u003e\n\u003cp\u003eThe structural modification itself also creates an important analytical research area. Changes to molecular structure can affect molecular mass, identity profile, solubility, stability and other physicochemical characteristics. Appropriate analytical techniques are therefore especially valuable when distinguishing RAD-150 from RAD-140 and confirming that the material being investigated corresponds to the intended compound.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Androgen Signalling Research Set, RAD-150 provides the less extensively characterised side of a closely related molecular pairing. This allows researchers to examine a newer SARM-category research compound alongside its better-documented relative while clearly separating established evidence from hypotheses.\u003c\/p\u003e\n\u003cp\u003eBioPlex supplies RAD-150 as a 50×15mg research capsule product and currently lists it at £38.99, reduced from its regular £48.99 price. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and SARMs-category research compounds from BioPlex.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg?utm_source=chatgpt.com\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-150 TLB-150 | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-150-tlb-150-br-50x15mg?utm_source=chatgpt.com\"\u003eView RAD-150 TLB-150 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Compounds ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"BioPlex Peptides | All Research Products\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering RAD-140, RAD-150, androgen-receptor signalling and the structural relationship between these two research compounds.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-150 TLB-150 Research Overview | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-150-tlb-150-research-overview?utm_source=chatgpt.com\"\u003eRead the RAD-150 TLB-150 Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"RAD-140 Testolone Research Overview | BioPlex Peptides\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-140-testolone-research-overview\"\u003eRead the RAD-140 Testolone Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"SARMs Research Articles | BioPlex Peptides UK\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"Legal Notice | BioPlex Peptides UK\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753167131008,"sku":null,"price":87.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/RAD-140_RAD-150.png?v=1787432066"},{"product_id":"yk-11-s-23","title":"YK-11 + S-23","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eYK-11 (Myostine) + S-23 (Mastorin) | SARMs Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eMyogenic Growth Pathway Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Myogenic Growth Pathway Research Set combines YK-11 (Myostine) 50×15mg and S-23 (Mastorin) 50×15mg, bringing together two experimental compounds associated with androgen-receptor research while offering distinctly different scientific profiles. The set contains one pot of each compound and provides a structured pairing for comparative laboratory investigation of androgen-receptor signalling, myogenic pathways and compound-specific molecular responses.\u003c\/p\u003e\n\u003cp\u003eYK-11 occupies an unusual position within the wider SARM research category. It is commonly grouped with selective androgen receptor modulators because research has demonstrated androgen-receptor-related activity, but its structure and available experimental evidence distinguish it from more conventional non-steroidal SARMs. Particular research interest has developed around its reported relationship with myogenic signalling and follistatin-associated observations, although these findings originate  primarily from limited cellular research and require careful interpretation.\u003c\/p\u003e\n\u003cp\u003eS-23, commonly known as Mastorin, is an experimental non-steroidal selective androgen receptor modulator investigated principally through androgen-receptor pathways. Its research profile therefore provides a useful comparison with YK-11, allowing two compounds associated with the same broad receptor system to be examined while recognising significant differences in their molecular structures and evidence bases.\u003c\/p\u003e\n\u003cp\u003eThe Myogenic Growth Pathway Research Set name reflects the scientific theme connecting the compounds rather than guaranteeing any particular experimental result. Myogenic signalling involves a complex network of receptors, transcription factors and regulatory proteins, and findings from one experimental system cannot automatically be transferred to another.\u003c\/p\u003e\n\u003cp\u003eBringing YK-11 and S-23 together consequently creates a research pairing centred on androgen-receptor biology while allowing YK-11's additional myogenic research questions to be considered separately. Both products remain individually identified 50×15mg capsule compounds supplied strictly for laboratory, analytical and educational research.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow YK-11 and S-23 Work Together\u003c\/h2\u003e\n\u003cp\u003eYK-11 (Myostine) and S-23 (Mastorin) are both associated with androgen-receptor research, providing the principal scientific connection between the compounds. The androgen receptor is a ligand-regulated nuclear receptor capable of influencing transcription of androgen-responsive genes following interaction with an appropriate ligand. Differences between individual ligands can nevertheless result in substantially different experimental profiles.\u003c\/p\u003e\n\u003cp\u003eS-23 fits more conventionally within the non-steroidal selective androgen receptor modulator category. Research involving the compound has focused on androgen-receptor activity and downstream responses across experimental models. YK-11 is more unusual. Although it demonstrates androgen-receptor-associated activity, its steroidal structural characteristics and limited evidence base mean it should not simply be treated as equivalent to conventional SARMs.\u003c\/p\u003e\n\u003cp\u003eThe additional research interest surrounding YK-11 comes from cellular studies examining myogenic differentiation and follistatin-associated expression. Follistatin is a regulatory protein capable of interacting with members of the transforming growth factor-beta superfamily, including activin-related signalling pathways. This has contributed to wider discussion of YK-11 in relation to myostatin-associated research, but the distinction between observed cellular findings and established whole-system effects is essential.\u003c\/p\u003e\n\u003cp\u003ePairing YK-11 with S-23 therefore provides a framework for studying shared androgen-receptor biology alongside potentially different downstream signalling characteristics. Researchers may compare receptor-associated responses, transcriptional markers and predetermined cellular endpoints while separately examining YK-11-specific hypotheses involving myogenic regulatory pathways.\u003c\/p\u003e\n\u003cp\u003eThe combination does not establish that the compounds are synergistic or that one enhances the activity of the other. Their different molecular characteristics, evidence levels and experimental histories make controlled comparison more appropriate than assuming a predetermined combined response.\u003c\/p\u003e\n\u003cp\u003eThe research value of this pairing therefore lies in investigating two distinct androgen-receptor-associated compounds within a common experimental framework while maintaining clear separation between established receptor pharmacology, preliminary cellular findings and hypotheses requiring further investigation.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eYK-11 (Myostine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eYK-11, commonly known as Myostine within the research-compound market, is an experimental androgen-receptor-associated compound that has attracted particular interest because of its unusual pharmacological and structural characteristics. Although frequently placed within the SARM category, YK-11 differs structurally from many better-known non-steroidal selective androgen receptor modulators and has a considerably smaller direct evidence base.\u003c\/p\u003e\n\u003cp\u003eLaboratory research has demonstrated androgen-receptor-associated activity, making receptor signalling an important part of YK-11 investigation. However, much of the wider scientific interest surrounding the compound originates from cellular research examining myogenic differentiation and associated regulatory pathways rather than extensive clinical investigation.\u003c\/p\u003e\n\u003cp\u003eOne frequently discussed area involves follistatin. Cellular research has reported changes in follistatin expression following YK-11 exposure under specific experimental conditions. Follistatin participates in complex signalling networks and can bind selected members of the TGF-beta superfamily. This relationship has led YK-11 to become widely discussed in connection with myostatin-related research.\u003c\/p\u003e\n\u003cp\u003eThat interpretation requires caution. Evidence of altered follistatin expression in a cellular model does not establish that YK-11 directly blocks myostatin or produces a predetermined tissue response across different biological systems. Myogenesis involves multiple interacting signalling pathways, transcription factors and regulatory proteins. Experimental model, concentration, exposure duration and endpoint selection can materially affect results.\u003c\/p\u003e\n\u003cp\u003eThis limited evidence base is one reason YK-11 is scientifically interesting within the Myogenic Growth Pathway Research Set. Rather than presenting hypotheses as established facts, researchers can examine its androgen-receptor-associated characteristics alongside selected myogenic markers and compare those observations with a more conventional SARM-category compound such as S-23.\u003c\/p\u003e\n\u003cp\u003eWithin this set, YK-11 therefore provides the myogenic-signalling-focused side of the pairing while retaining its relationship with wider androgen-receptor research.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eS-23 (Mastorin) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eS-23, commonly known as Mastorin within the research-compound market, is an experimental non-steroidal selective androgen receptor modulator studied principally for its interaction with the androgen receptor. Its pharmacological classification places it within the genuine SARM research category, distinguishing it from related compounds sometimes sold alongside SARMs that instead target completely different molecular pathways.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor functions as a ligand-activated nuclear receptor and transcriptional regulator. Following interaction with an appropriate ligand, receptor conformation and co-regulatory interactions can change, potentially altering transcription of androgen-responsive genes. S-23 research is therefore centred primarily on this receptor system and downstream experimental responses associated with its modulation.\u003c\/p\u003e\n\u003cp\u003eS-23 remains an investigational compound. Its research history includes preclinical investigation, but this does not establish approved applications or allow observations from experimental models to be generalised beyond the conditions studied. Concentration, exposure, tissue environment, receptor expression and experimental methodology remain important variables when interpreting findings.\u003c\/p\u003e\n\u003cp\u003eWithin this set, S-23 provides an interesting counterpart to YK-11. Both compounds are associated with androgen-receptor research, but their molecular characteristics and evidence profiles differ. YK-11 has generated additional research interest around myogenic and follistatin-associated observations, whereas S-23 provides a more conventional selective androgen receptor modulator framework.\u003c\/p\u003e\n\u003cp\u003eThis distinction allows researchers to consider common androgen-receptor signalling while examining whether compound-specific molecular characteristics correspond with different downstream observations. It also prevents the broad SARM classification from obscuring meaningful differences between the two molecules.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Myogenic Growth Pathway Research Set, S-23 therefore provides the second androgen-receptor-focused component of a comparative research pairing and complements the more specialised myogenic research questions associated with YK-11.\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and SARMs-category research compounds from BioPlex.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"YK-11 Myostine | Research SARM Capsules | BioPlex UK\"\u003eView YK-11 Myostine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"S-23 Mastorin | Research SARM Capsules | BioPlex UK\"\u003eView S-23 Mastorin 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\" title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all\" title=\"BioPlex Peptides | All Research Products\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering SARMs, androgen-receptor signalling, YK-11-related research pathways and compound classification.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?\" title=\"YK-11 S-23 and SARMs Research Guide | BioPlex Peptides\"\u003eRead the Complete Guide to SARMs UK: Research Compounds Explained ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-140-testolone-research-overview\" title=\"RAD-140 Testolone Androgen Receptor Research Overview | BioPlex Peptides\"\u003eRead the RAD-140 Testolone Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\"\u003eFor research purposes only. Not for human consumption\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mt-3 w-full empty:hidden has-[\u0026gt;_:empty]:hidden\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BioPlexPeptides.co.uk","offers":[{"title":"Default Title","offer_id":58753175257472,"sku":null,"price":82.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/YK-11_S-23.png?v=1787432199"},{"product_id":"ac-262-acp-105","title":"AC-262 + ACP-105","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eAC-262 (Accadrine) + ACP-105 (Androxepen) | SARMs Research UK\u003c\/h2\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eSelective Muscle Tissue Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Selective Muscle Tissue Research Set combines AC-262 (Accadrine) 50×15mg and ACP-105 (Androxepen) 50×15mg, bringing together two non-steroidal selective androgen receptor modulators for comparative laboratory investigation of androgen-receptor signalling, tissue-selective responses and differences between distinct experimental SARM compounds. The set contains one pot of each compound and provides a structured format for studying two molecules that share the androgen receptor as an important molecular target while retaining separate chemical structures and evidence profiles.\u003c\/p\u003e\n\u003cp\u003eAC-262, also identified in scientific literature as AC-262,536, is particularly associated with research into selective androgen-receptor modulation and partial agonist behaviour. Published investigation has examined its receptor-binding characteristics, transcriptional activity and responses across experimental tissue models. This makes AC-262 particularly relevant to questions concerning whether androgen-receptor signalling can produce different patterns of activity according to ligand structure and biological environment.\u003c\/p\u003e\n\u003cp\u003eACP-105 is another experimental non-steroidal selective androgen receptor modulator associated with tissue-selective androgen-receptor research. Its molecular structure differs from AC-262, and the available research surrounding the two compounds should therefore be evaluated independently rather than assuming that membership of the same pharmacological category makes their behaviour equivalent.\u003c\/p\u003e\n\u003cp\u003eThe Selective Muscle Tissue Research Set name reflects the wider scientific interest surrounding tissue-selective androgen-receptor signalling. It does not imply that either compound will produce a predetermined experimental outcome.\u003c\/p\u003e\n\u003cp\u003eBy bringing AC-262 and ACP-105 together, BioPlex provides a comparative research pairing centred on two distinct androgen-receptor ligands. Researchers can examine similarities in their broad receptor pathway while considering differences in molecular structure, receptor activity, evidence depth and experimentally observed tissue responses. Both compounds are supplied as individually identified 50×15mg capsule products intended strictly for laboratory, analytical and educational research.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eHow AC-262 and ACP-105 Work Together\u003c\/h2\u003e\n\u003cp\u003eAC-262 (Accadrine) and ACP-105 (Androxepen) are connected principally through their classification as experimental selective androgen receptor modulators. The androgen receptor is a ligand-activated nuclear receptor that can regulate transcription of androgen-responsive genes following interaction with an appropriate ligand. This shared molecular target provides the principal scientific rationale for placing the compounds together within a comparative research set.\u003c\/p\u003e\n\u003cp\u003eThe term selective is important. SARM research has investigated whether structurally different androgen-receptor ligands can generate different patterns of receptor activation and tissue response rather than reproducing identical activity across every androgen-responsive experimental system. Ligand structure, receptor conformation, co-regulator recruitment, receptor density and cellular environment can all contribute to the resulting response.\u003c\/p\u003e\n\u003cp\u003eAC-262 is particularly interesting because published research has described partial agonist characteristics within androgen-receptor investigation. Partial agonism means that receptor binding alone does not necessarily translate into the same maximal receptor response observed with a full agonist under comparable experimental conditions. BioPlex's existing AC-262 research material accordingly focuses on receptor signalling, partial agonism and tissue-selective research. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eACP-105 provides a second structurally distinct androgen-receptor ligand. Pairing it with AC-262 therefore allows researchers to consider whether separate compounds within the SARM category display differing receptor-associated responses when examined using equivalent analytical conditions.\u003c\/p\u003e\n\u003cp\u003eThis does not establish that AC-262 and ACP-105 are synergistic or that combining them produces an enhanced biological effect. Their scientific value as a pairing lies instead in comparative investigation.\u003c\/p\u003e\n\u003cp\u003eControlled research can examine receptor activation, transcriptional markers and tissue-dependent responses while maintaining clear separation between findings attributable to each compound. Appropriate controls, verified compound identity, defined experimental conditions and predetermined endpoints remain essential when interpreting observations involving either molecule.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eAC-262 (Accadrine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eAC-262, commonly known as Accadrine and identified scientifically as AC-262,536, is a synthetic non-steroidal selective androgen receptor modulator investigated primarily through receptor-binding, transcriptional and preclinical research. It occupies an interesting position within the SARM category because published investigation has characterised it in relation to partial agonist activity at the androgen receptor and tissue-dependent experimental responses.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor is AC-262's principal molecular research target. As a nuclear receptor, it can influence transcription following ligand binding and subsequent interaction with regulatory proteins and androgen-response elements. However, receptor binding does not by itself determine the complete biological response. Ligand structure, receptor conformation, co-regulator recruitment and the characteristics of the experimental tissue can all influence downstream observations.\u003c\/p\u003e\n\u003cp\u003ePublished AC-262 research has concentrated substantially on early pharmacological and preclinical models. This distinguishes its evidence profile from SARMs such as Ostarine, which have progressed through considerably broader research programmes. BioPlex's comparative research material describes AC-262 as structurally distinct and highlights its association with partial agonist behaviour and tissue-selective androgen-receptor investigation. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eThis makes AC-262 useful when investigating an important principle within SARM pharmacology: compounds interacting with the same receptor do not necessarily generate identical levels or patterns of receptor activation.\u003c\/p\u003e\n\u003cp\u003eWithin the Selective Muscle Tissue Research Set, AC-262 therefore provides one side of a structured comparison between two distinct non-steroidal androgen-receptor ligands. Researchers can consider its documented partial-agonist characteristics alongside the separate molecular and experimental profile of ACP-105.\u003c\/p\u003e\n\u003cp\u003eBioPlex also maintains dedicated educational material covering AC-262, including androgen-receptor signalling, SARM selectivity, partial agonist activity, tissue-marker research and analytical testing. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eACP-105 (Androxepen) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eACP-105, presented by BioPlex under the Androxepen name, is an experimental non-steroidal selective androgen receptor modulator associated with research into androgen-receptor signalling and tissue-selective pharmacology. Like other genuine SARMs, its scientific classification centres on interaction with the androgen receptor rather than unrelated metabolic, growth-hormone or nuclear-receptor pathways.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor functions as a ligand-regulated transcription factor. Interaction with an appropriate ligand can change receptor conformation and influence subsequent interactions with cellular co-regulators and DNA response elements. These processes can affect androgen-responsive transcription, although the resulting experimental profile depends upon both the ligand and the biological system in which it is studied.\u003c\/p\u003e\n\u003cp\u003eACP-105 is a distinct molecule and should therefore not be treated as interchangeable with AC-262 simply because both compounds belong to the broad SARM category. Differences in chemical structure may correspond with differences in receptor interaction, pharmacological characteristics and tissue-dependent responses. Compound-specific investigation is required to establish those differences.\u003c\/p\u003e\n\u003cp\u003eThis is particularly relevant within comparative SARM research. The objective is not simply to determine whether two molecules can interact with the same receptor. Researchers may instead investigate differences in receptor activation, transcriptional signalling, tissue selectivity and other predefined experimental endpoints.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Selective Muscle Tissue Research Set, ACP-105 provides a useful counterpart to AC-262. AC-262 brings a research profile particularly associated with partial agonism and early-stage tissue-selectivity investigation, while ACP-105 provides a separate androgen-receptor ligand for comparative analysis.\u003c\/p\u003e\n\u003cp\u003eThe current BioPlex SARMs catalogue identifies ACP-105 Androxepen as a 50×15mg research capsule product and lists it alongside AC-262 and other androgen-receptor research compounds. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3 class=\"PDq2pG_selectionAnchorContainer\"\u003eExplore Related Research Compounds\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related selective androgen receptor modulators from the BioPlex SARMs capsule range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/ac-262-accadrine-br-50x15mg\" title=\"AC-262 Accadrine | Research SARM Capsules | BioPlex UK\"\u003eView AC-262 Accadrine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"ACP-105 Androxepen | Research SARM Capsules | BioPlex UK\"\u003eExplore ACP-105 Androxepen 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\" title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003ch3\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering AC-262 Accadrine, androgen-receptor signalling, partial agonist activity and comparative SARM research.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"AC-262 Accadrine Research Overview | BioPlex Peptides\"\u003eRead the AC-262 Accadrine Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/de\/blogs\/sarms-research-articles-bioplex-peptides-uk\/h1-science-research-studies-ac-262-vs-ostarine-mk-2866-androgen-receptor-research-compared\" title=\"AC-262 vs Ostarine MK-2866 | Androgen Receptor Research | BioPlex Peptides\"\u003eRead AC-262 vs Ostarine MK-2866: Androgen-Receptor Research Compared ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"SARMs Research Articles | BioPlex Peptides UK\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"Legal Notice | BioPlex Peptides UK\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753192886656,"sku":null,"price":89.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/AC-262_ACP-105.png?v=1787432354"},{"product_id":"sr-9009-sr-9011","title":"SR-9009 + SR-9011","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eSR-9009 (Stenabolic) + SR-9011 (REV-ERB Agonist) | Metabolic Research UK\u003c\/h2\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003e\n\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003eMetabolic Activity Research Set \u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Metabolic Activity Research Set combines SR-9009 (Stenabolic) 50×15mg and SR-9011 (REV-ERB Agonist) 50×15mg, bringing together two closely related synthetic research compounds developed for investigation of REV-ERB-associated signalling, circadian biology and metabolic regulation. The set contains one pot of each compound and provides a structured format for comparative laboratory research into two molecules that share a closely connected research history while retaining distinct chemical identities.\u003c\/p\u003e\n\u003cp\u003eUnlike compounds such as RAD-140, Ostarine or LGD-4033, SR-9009 and SR-9011 are not selective androgen receptor modulators. Their research history instead centres on REV-ERBα and REV-ERBβ, nuclear receptors involved in biological pathways connecting circadian rhythms, transcriptional regulation and cellular metabolism. This distinction is important when interpreting the scientific purpose of the set.\u003c\/p\u003e\n\u003cp\u003eSR-9009, widely known as Stenabolic, is the better-known of the two compounds and has been investigated in experimental models examining circadian behaviour, metabolic gene expression, mitochondrial-associated processes and energy metabolism. SR-9011 was developed within the same broader research programme and provides a related synthetic ligand for studying REV-ERB-associated pathways.\u003c\/p\u003e\n\u003cp\u003eTheir close relationship makes this pairing useful for comparative laboratory investigation. Rather than combining unrelated mechanisms, researchers can examine two structurally distinct compounds developed around the same nuclear-receptor research system.\u003c\/p\u003e\n\u003cp\u003eThe Metabolic Activity Research Set name reflects this principal scientific theme. It does not imply that either compound will produce predetermined metabolic outcomes, and later research has raised important questions about whether all experimental observations attributed to SR-9009 are mediated exclusively through REV-ERB.\u003c\/p\u003e\n\u003cp\u003eTogether, SR-9009 and SR-9011 provide a focused BioPlex pairing for laboratory investigation of metabolic signalling, circadian pathways and REV-ERB-associated research while maintaining appropriate distinction between established findings and mechanistic hypotheses.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow SR-9009 and SR-9011 Work Together\u003c\/h2\u003e\n\u003cp\u003eSR-9009 and SR-9011 were developed as synthetic compounds for investigating REV-ERB-associated signalling. REV-ERBα and REV-ERBβ are members of the nuclear-receptor family and participate in transcriptional networks connecting the molecular circadian clock with metabolic regulation. This shared research pathway provides the scientific rationale for presenting SR-9009 and SR-9011 together.\u003c\/p\u003e\n\u003cp\u003eREV-ERB receptors participate in regulation of gene expression rather than functioning through the androgen receptor targeted by genuine SARMs. This makes the SR pairing mechanistically different from the androgen-receptor combinations elsewhere in the BioPlex research range.\u003c\/p\u003e\n\u003cp\u003eExperimental investigation of synthetic REV-ERB ligands has examined pathways associated with circadian regulation, metabolic gene expression, lipid and glucose metabolism, mitochondrial function and energy-related cellular processes. SR-9009 and SR-9011 have consequently become useful experimental tools for investigating how pharmacological modulation of these pathways may alter measurable biological markers.\u003c\/p\u003e\n\u003cp\u003eHowever, their relationship should not be oversimplified. Two compounds developed against the same receptor system do not necessarily demonstrate identical potency, selectivity, pharmacokinetics or downstream experimental effects. Chemical structure, concentration, cellular environment and experimental model can influence observations.\u003c\/p\u003e\n\u003cp\u003eThere is another important scientific consideration. Later research involving SR-9009 reported biological effects that persisted in experimental systems lacking functional REV-ERBα\/β, raising evidence that at least some effects of SR-9009 can occur independently of REV-ERB. Consequently, describing every observed SR-9009 response as a direct result of REV-ERB activation would overstate the evidence.\u003c\/p\u003e\n\u003cp\u003eThe value of this combination therefore lies in controlled comparison rather than assuming synergy. SR-9009 and SR-9011 allow researchers to investigate two related synthetic ligands within circadian and metabolic research while examining receptor-dependent and potentially receptor-independent mechanisms under carefully defined experimental conditions.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eSR-9009 (Stenabolic) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9009, commonly known as Stenabolic, is a synthetic research compound developed during investigation of the nuclear receptors REV-ERBα and REV-ERBβ. Although frequently grouped commercially with SARMs, SR-9009 is not a selective androgen receptor modulator and does not belong to the same primary pharmacological category as compounds such as Ostarine, RAD-140 or LGD-4033.\u003c\/p\u003e\n\u003cp\u003eIts research significance originates from the role of REV-ERB receptors in the molecular circadian clock and metabolic regulation. Nuclear receptors can influence transcriptional activity in response to molecular interactions, and REV-ERB proteins participate in networks regulating circadian gene expression and metabolic processes.\u003c\/p\u003e\n\u003cp\u003eEarly experimental research using SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could alter measurable circadian and metabolic parameters. This produced research interest in areas including metabolic gene expression, energy utilisation, mitochondrial-associated activity and related cellular processes.\u003c\/p\u003e\n\u003cp\u003eHowever, subsequent research complicated the original mechanistic interpretation. Experimental studies have reported SR-9009-associated effects in models where REV-ERB activity was absent or disrupted. These findings indicate that at least some observations associated with SR-9009 may involve mechanisms beyond direct REV-ERB activation.\u003c\/p\u003e\n\u003cp\u003eThis distinction is scientifically important. SR-9009 remains valuable as an experimental research compound, but results should not automatically be interpreted as proof of a purely REV-ERB-dependent mechanism. Researchers should distinguish between observed biological responses and conclusions about the precise molecular pathway producing those responses.\u003c\/p\u003e\n\u003cp\u003eWithin the Metabolic Activity Research Set, SR-9009 provides the better-known component of the pairing. Its extensive use in metabolic and circadian research provides a useful comparison point for SR-9011 while allowing receptor-specific hypotheses, alternative mechanisms and compound-dependent experimental differences to be investigated independently.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eSR-9011 (REV-ERB Agonist) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9011 is a synthetic research compound developed within the same broader programme of investigation into pharmacological modulation of REV-ERB nuclear receptors as SR-9009. It is commonly described within scientific and research-compound literature as a synthetic REV-ERB ligand or agonist and has been investigated in experimental systems involving circadian regulation, transcriptional signalling and metabolic biology.\u003c\/p\u003e\n\u003cp\u003eLike SR-9009, SR-9011 is not a selective androgen receptor modulator. Its principal research classification instead relates to REV-ERBα and REV-ERBβ, nuclear receptors that participate in transcriptional networks connecting circadian timing with metabolic processes.\u003c\/p\u003e\n\u003cp\u003eThis pathway makes SR-9011 useful for laboratory investigation of how synthetic ligands may influence REV-ERB-associated transcription and downstream biological markers. Experimental areas can include circadian gene expression, cellular metabolic signalling and other predetermined endpoints relevant to nuclear-receptor biology.\u003c\/p\u003e\n\u003cp\u003eSR-9011 should nevertheless be evaluated independently rather than assuming that every observation made with SR-9009 applies equally to it. Structurally related compounds can differ in receptor interaction, concentration-response relationships, stability, cellular exposure and off-target behaviour. These differences are particularly important when the objective of research is to understand mechanism rather than simply document an observed response.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Metabolic Activity Research Set, SR-9011 therefore provides the second component of a closely related comparative pairing. SR-9009 offers the larger and more widely discussed experimental history, while SR-9011 enables investigation of another synthetic compound associated with the same broader nuclear-receptor pathway.\u003c\/p\u003e\n\u003cp\u003eUsed as separate experimental compounds within the same research framework, SR-9009 and SR-9011 can support comparative investigation of REV-ERB-associated signalling, circadian biology and metabolic pathways without incorrectly classifying either compound as a SARM or assuming that their experimental behaviour is identical.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related metabolic, nuclear-receptor and research compounds from the BioPlex range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9009 Stenabolic | Metabolic Research Capsules | BioPlex UK\"\u003eView SR-9009 Stenabolic 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9011 REV-ERB Agonist | Metabolic Research Capsules | BioPlex UK\"\u003eView SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"MK-677 Ibutamoren | Research Capsules | BioPlex UK\"\u003eView MK-677 Ibutamoren 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SARMs and Related Research Compounds Guide 2026 | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs and Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering compound classification, metabolic research compounds and the distinction between SARMs and compounds operating through different molecular pathways.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-mk-677-ibutamoren-is-not-a-sarm\" title=\"MK-677 Ibutamoren Is Not a SARM | Research Classification | BioPlex Peptides\"\u003eRead Why MK-677 Ibutamoren Is Not a SARM ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SR-9009 SR-9011 and Research Compound Classification | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753225851264,"sku":null,"price":93.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/SR-9009_SR-9011.png?v=1787432562"},{"product_id":"mk-677-mk-777","title":"MK-677 + MK-777","description":"\u003ch2\u003e\u003cspan\u003eMK-677 (Ibutamoren) + MK-777 (Acetamoren) | Growth-Factor Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eGrowth-Factor Signalling Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Growth-Factor Signalling Research Set combines MK-677 (Ibutamoren) 50×15mg and MK-777 (Acetamoren) 50×15mg, bringing together two synthetic, non-peptide research compounds associated with growth-hormone secretagogue and related signalling research. The set contains one pot of each compound and provides a structured pairing for comparative laboratory investigation of two molecules that are frequently grouped within the same research-compound category while possessing very different levels of supporting scientific evidence.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 is the substantially better-characterised compound. Also known as Ibutamoren, MK-0677 and L-163,191, it has been investigated as a synthetic agonist of the growth hormone secretagogue receptor, commonly referred to as GHS-R1a or the ghrelin receptor. This receptor pathway connects ghrelin signalling with growth-hormone release and downstream endocrine markers including insulin-like growth factor-1. MK-677 research has consequently examined receptor activation, growth-hormone signalling, IGF-1 responses, metabolic variables and additional physiological endpoints across different experimental settings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly referred to as Acetamoren, is a much newer research-compound designation. It is frequently positioned alongside MK-677 within commercial research catalogues and associated with growth-hormone-secretagogue research themes. However, the accessible compound-specific pharmacological evidence for MK-777 is currently far more limited than the published evidence surrounding Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Growth-Factor Signalling Research Set name therefore reflects the broader scientific theme connecting these compounds without implying that their mechanisms or biological behaviour are proven to be identical.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eBy presenting MK-677 and MK-777 together while clearly separating established evidence from emerging research claims, BioPlex provides a comparative format for investigating growth-hormone-associated signalling, compound classification and the importance of evidence quality within modern research-compound analysis.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow MK-677 and MK-777 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 (Ibutamoren) and MK-777 (Acetamoren) are grouped together because both are associated with research surrounding growth-hormone secretagogue signalling rather than conventional androgen-receptor modulation. This makes the pairing mechanistically different from genuine SARMs such as RAD-140, LGD-4033 or Ostarine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 has a well-established relationship with the growth hormone secretagogue receptor, also known as GHS-R1a or the ghrelin receptor. Ghrelin is an endogenous signalling molecule that interacts with this receptor, while MK-677 acts as a synthetic, non-peptide receptor agonist in established research models. Activation of this pathway has been studied in relation to growth-hormone secretion, downstream IGF-1 signalling, appetite-associated mechanisms, metabolic regulation and other endocrine variables.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 is commonly positioned within a related research category, but its direct compound-specific evidence is substantially less developed. It should therefore not automatically be assumed that MK-777 interacts with the same receptor with the same affinity, produces equivalent downstream signalling or shares MK-677's established pharmacological profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis difference in evidence strength is precisely what makes the pairing scientifically useful. Researchers can examine an established growth-hormone-secretagogue research compound alongside a newer and less extensively characterised molecule while distinguishing demonstrated receptor pharmacology from proposed classification.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination does not establish that MK-677 and MK-777 are synergistic or that one enhances the activity of the other. Nor should evidence obtained with Ibutamoren simply be transferred to Acetamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin controlled laboratory investigation, the set provides a framework for comparing compound identity, proposed receptor pathways, endocrine-signalling hypotheses and analytical characteristics. Appropriate controls, validated compound identification and clearly defined research endpoints remain essential when interpreting findings involving either molecule.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-677 (Ibutamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677, commonly known as Ibutamoren and also identified as MK-0677 or L-163,191, is a synthetic non-peptide research compound studied primarily as a growth hormone secretagogue and ghrelin-receptor agonist. Although MK-677 is frequently grouped commercially with SARMs, it is not scientifically classified as a selective androgen receptor modulator because its principal established mechanism does not involve selective modulation of the androgen receptor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eInstead, MK-677 interacts with the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor. This receptor normally responds to the endogenous hormone ghrelin and participates in signalling pathways associated with growth-hormone secretion, appetite regulation, endocrine activity and metabolic processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving MK-677 has examined its ability to activate this receptor pathway and influence downstream markers including growth hormone and insulin-like growth factor-1. Other research settings have explored metabolic variables, body-composition measurements, sleep-related endpoints, appetite-associated signalling and endocrine responses. The breadth of this research makes MK-677 one of the better-characterised compounds within the wider growth-hormone-secretagogue category.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eNevertheless, the existence of a substantial research history does not mean that every popular claim concerning MK-677 is scientifically established. Observations depend upon study design, experimental population or model, exposure, duration and measured endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Growth-Factor Signalling Research Set, MK-677 therefore provides the established pharmacological reference compound. Its recognised ghrelin-receptor mechanism and comparatively extensive evidence base can be examined alongside the far less characterised MK-777 Acetamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction is especially useful for comparative research because it allows well-supported receptor pharmacology to remain separate from emerging compound classifications and hypotheses that require additional experimental confirmation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-777 (Acetamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly referred to as Acetamoren, is a synthetic non-peptide research compound that has appeared more recently within research-compound catalogues. It is frequently discussed alongside MK-677 Ibutamoren and associated with growth-hormone-secretagogue research, but its scientific evidence base is substantially less developed than that of MK-677.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis difference is important. MK-677 has a documented pharmacological relationship with the growth hormone secretagogue receptor and a substantial published research history. MK-777 does not currently have the same accessible body of compound-specific pharmacological evidence establishing its receptor affinity, signalling characteristics, pharmacokinetics or downstream biological effects.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eConsequently, the Acetamoren name and its placement within a particular research category should not be treated as sufficient evidence that MK-777 behaves identically to Ibutamoren. Structural similarity, commercial categorisation or related naming conventions cannot replace direct compound-specific receptor and pharmacological research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis makes analytical identification especially relevant when investigating MK-777. Researchers may examine compound identity, molecular characteristics, purity, proposed classification and experimental behaviour while distinguishing confirmed observations from assumptions derived from better-characterised compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the BioPlex Growth-Factor Signalling Research Set, MK-777 provides the emerging research component of the pairing. MK-677 offers an established ghrelin-receptor and growth-hormone-secretagogue reference point, while MK-777 allows newer Acetamoren-related hypotheses to be examined independently.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value of this combination therefore comes from comparison rather than from assuming equivalence. Researchers can investigate two compounds positioned within related research themes while maintaining clear separation between established MK-677 pharmacology and the considerably more limited evidence presently available for MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis evidence-led approach also helps prevent broad commercial categories from being mistaken for validated molecular classifications.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related growth-hormone secretagogue and research compounds from the BioPlex capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-677-ibutamoren-br-50x15mg\" title=\"MK-677 Ibutamoren | Growth Hormone Secretagogue Research | BioPlex UK\"\u003e\u003cspan\u003eView MK-677 Ibutamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-777-acetamoren-br-50x15mg\" title=\"MK-777 Acetamoren | Research Compound Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-777 Acetamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Related Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore All BioPlex SARMs \u0026amp; Related Research Compounds ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SARMs \u0026amp; Related Research Compounds Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering MK-677 Ibutamoren, MK-777 Acetamoren, growth-hormone secretagogue signalling and compound classification.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-677-ibutamoren-research-overview\" title=\"MK-677 Ibutamoren Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-677 Ibutamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-777-acetamoren-research-overview-research-studies\" title=\"MK-777 Acetamoren Research Overview \u0026amp; Research Studies | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-777 Acetamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-mk-777-vs-mk-677-compound-classification-research-pathways-and-key-differences\" title=\"MK-777 vs MK-677 | Compound Classification \u0026amp; Research Pathways | BioPlex Peptides\"\u003e\u003cspan\u003eRead MK-777 vs MK-677: Research Pathways \u0026amp; Key Differences ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753234534784,"sku":null,"price":88.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MK-677_MK-777.png?v=1787432748"},{"product_id":"sr-9009-gw-0742","title":"SR-9009 + GW-0742","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eSR-9009 (Stenabolic) + GW-0742 (Fitorine) | Metabolic Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eMetabolic Recomposition Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Metabolic Recomposition Research Set combines SR-9009 (Stenabolic) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two synthetic research compounds associated with distinct molecular pathways involved in metabolic regulation. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of REV-ERB-associated and PPARδ-associated signalling within a broader metabolic research framework. \u003c\/p\u003e\n\u003cp\u003eNeither SR-9009 nor GW-0742 is a selective androgen receptor modulator. This distinction is important because both compounds are sometimes commercially grouped alongside SARMs despite operating through fundamentally different areas of molecular research. SR-9009 was developed during research into REV-ERB nuclear receptors and has been investigated across circadian, transcriptional and metabolic experimental models. GW-0742 is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ, and has been used experimentally to investigate lipid metabolism, cellular signalling and other PPAR-regulated pathways.\u003c\/p\u003e\n\u003cp\u003eThis difference creates the principal scientific interest of the pairing. Instead of examining two compounds directed toward the same receptor, researchers can compare separate regulatory pathways that intersect with broader questions concerning cellular metabolism and gene expression.\u003c\/p\u003e\n\u003cp\u003eThe Metabolic Recomposition Research Set name reflects this shared research theme rather than implying that either compound produces a predetermined physiological result. Metabolic regulation involves interconnected receptor systems, transcription factors, enzymes and cellular responses, making controlled experimental interpretation essential.\u003c\/p\u003e\n\u003cp\u003eBy bringing SR-9009 and GW-0742 together while maintaining clear separation between their mechanisms, BioPlex provides a comparative research format for investigating two distinct metabolic-signalling compounds. Both products remain individually identified 50×15mg capsule compounds supplied strictly for laboratory, analytical and educational research.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow SR-9009 and GW-0742 Work Together\u003c\/h2\u003e\n\u003cp\u003eSR-9009 (Stenabolic) and GW-0742 (Fitorine) are scientifically interesting as a research pairing because they are associated with different nuclear-receptor pathways connected to metabolic regulation. Rather than sharing a single molecular target, the compounds provide two separate experimental approaches for examining transcriptional and cellular processes involved in metabolism.\u003c\/p\u003e\n\u003cp\u003eSR-9009 was originally developed and investigated as a synthetic ligand associated with REV-ERBα and REV-ERBβ. REV-ERB proteins are nuclear receptors involved in transcriptional networks connecting circadian timing with metabolic regulation. Experimental investigation of SR-9009 has consequently examined circadian behaviour, metabolic gene expression, mitochondrial-associated processes and energy-related cellular pathways.\u003c\/p\u003e\n\u003cp\u003eGW-0742 is associated primarily with PPARδ, another nuclear receptor involved in transcriptional regulation. PPARδ participates in biological pathways associated with lipid handling, fatty-acid metabolism and cellular energy regulation. Experimental PPARδ agonists have therefore become useful tools for investigating how receptor activation influences downstream transcription and metabolic markers.\u003c\/p\u003e\n\u003cp\u003ePlacing the two compounds together allows researchers to consider these separate pathways within a common metabolic research framework. REV-ERB-associated signalling can be investigated alongside PPARδ-associated signalling while maintaining compound-specific controls and endpoints.\u003c\/p\u003e\n\u003cp\u003eThis does not establish that SR-9009 and GW-0742 are synergistic or that one compound enhances the activity of the other. The pathways are biologically complex, and observed responses may vary substantially according to experimental model, concentration, exposure and cellular environment.\u003c\/p\u003e\n\u003cp\u003eThere are also mechanistic limitations to consider. Later SR-9009 research has raised questions about whether all observed effects are dependent exclusively on REV-ERB, making careful interpretation particularly important.\u003c\/p\u003e\n\u003cp\u003eThe value of the pairing therefore lies in comparative pathway investigation: two different synthetic compounds, two distinct areas of nuclear-receptor research and a shared broader interest in metabolic regulation.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eSR-9009 (Stenabolic) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9009, commonly known as Stenabolic, is a synthetic research compound originally developed during investigation of REV-ERBα and REV-ERBβ nuclear receptors. Despite frequently appearing alongside SARMs within commercial research-compound categories, SR-9009 is not a selective androgen receptor modulator and should not be described as acting primarily through androgen-receptor signalling.\u003c\/p\u003e\n\u003cp\u003eREV-ERB proteins participate in transcriptional networks connecting circadian regulation with metabolic processes. These nuclear receptors form part of the molecular machinery involved in controlling patterns of gene expression over biological time cycles while also interacting with pathways associated with cellular metabolism.\u003c\/p\u003e\n\u003cp\u003eEarly research involving SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could influence measurable metabolic and circadian endpoints. This generated experimental interest in metabolic gene expression, mitochondrial-associated activity, energy regulation and related biological markers.\u003c\/p\u003e\n\u003cp\u003eHowever, subsequent research introduced an important qualification. Experimental work has reported SR-9009-associated effects in systems where functional REV-ERB activity was absent or disrupted. These observations suggest that at least some responses associated with SR-9009 may occur through mechanisms that are not exclusively dependent upon REV-ERB.\u003c\/p\u003e\n\u003cp\u003eThis means SR-9009 remains useful as an experimental compound while requiring greater care when interpreting mechanism. An observed response following exposure should not automatically be treated as proof of direct REV-ERB-mediated activity.\u003c\/p\u003e\n\u003cp\u003eWithin the Metabolic Recomposition Research Set, SR-9009 therefore provides the REV-ERB-associated side of the pairing. Its research history can be compared with the distinctly different PPARδ-associated profile of GW-0742.\u003c\/p\u003e\n\u003cp\u003eThis arrangement enables researchers to examine separate metabolic-signalling pathways within the same broader experimental theme while retaining appropriate controls, compound-specific interpretation and clear distinction between observed responses and proposed molecular mechanisms.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eGW-0742 (Fitorine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eGW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, usually abbreviated PPARδ. This classification separates GW-0742 from genuine selective androgen receptor modulators because its principal research pathway involves a different member of the nuclear-receptor superfamily.\u003c\/p\u003e\n\u003cp\u003ePPARδ functions as a transcriptional regulator. Following ligand interaction, PPAR-associated signalling can influence expression of genes involved in several metabolic and cellular processes. PPARδ research has consequently included investigation of lipid metabolism, fatty-acid handling, cellular energy regulation and other receptor-dependent biological pathways.\u003c\/p\u003e\n\u003cp\u003eGW-0742 has been used experimentally as a pharmacological tool for studying PPARδ-associated activity. Its value in laboratory research comes from allowing investigators to examine how modulation of this receptor corresponds with changes in predetermined molecular or cellular endpoints.\u003c\/p\u003e\n\u003cp\u003eHowever, receptor classification should not be interpreted as guaranteeing a particular biological result. Experimental observations depend upon concentration, exposure, receptor expression, tissue or cell type and methodology. Potential off-target activity and model-specific responses also need to be considered when drawing mechanistic conclusions.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Metabolic Recomposition Research Set, GW-0742 provides a distinctly different molecular pathway from SR-9009. Whereas SR-9009 is associated historically with REV-ERB research, GW-0742 provides a PPARδ-focused experimental compound.\u003c\/p\u003e\n\u003cp\u003eThis distinction makes the pairing particularly useful for comparative metabolic research. Researchers can examine two separate nuclear-receptor-associated pathways without incorrectly assuming that the compounds possess identical mechanisms.\u003c\/p\u003e\n\u003cp\u003eThe purpose of the pairing is therefore not to claim an enhanced combined effect. Instead, GW-0742 and SR-9009 provide two research tools for investigating different aspects of transcriptional and metabolic signalling under controlled laboratory conditions.\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related metabolic and cellular-signalling research compounds from the BioPlex range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SR-9009 Stenabolic | Metabolic Research Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eView SR-9009 Stenabolic 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"GW-0742 Fitorine | PPARδ Research Compound | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eView GW-0742 Fitorine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs \u0026amp; Related Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs \u0026amp; Related Research Compounds ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"SARMs \u0026amp; Related Research Compounds Guide 2026 | BioPlex Peptides\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"SARMs \u0026amp; Research Compounds UK | BioPlex Peptides\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca class=\"decorated-link\" rel=\"noopener\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products?utm_source=chatgpt.com\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering metabolic research compounds, compound classification and molecular pathways distinct from conventional androgen-receptor SARMs.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SR-9009 GW-0742 \u0026amp; Research Compound Classification | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore BioPlex SARMs \u0026amp; Research Compound Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753287684480,"sku":null,"price":88.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/SR-9009_GW-0742.png?v=1787433032"},{"product_id":"mk-2866-gw-0742","title":"MK-2866 + GW-0742","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eMK-2866 (Ostarine) + GW-0742 (Fitorine) | SARMs \u0026amp; Metabolic Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eLean Tissue \u0026amp; Metabolic Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Lean Tissue \u0026amp; Metabolic Research Set combines MK-2866 (Ostarine) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two research compounds associated with distinctly different molecular pathways. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of androgen-receptor signalling alongside PPARδ-associated metabolic signalling.\u003c\/p\u003e\n\u003cp\u003eMK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is a non-steroidal selective androgen receptor modulator. Its research history includes investigation of androgen-receptor activity, tissue-selective signalling, lean-tissue-related measurements and other controlled biological endpoints. This makes Ostarine one of the more extensively characterised compounds within the wider SARM research category.\u003c\/p\u003e\n\u003cp\u003eGW-0742, presented by BioPlex as Fitorine, belongs to a different pharmacological research category. It is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. PPARδ is a nuclear receptor involved in transcriptional regulation across metabolic pathways including lipid and fatty-acid handling. GW-0742 should therefore not be classified as a SARM simply because it is sometimes grouped commercially alongside selective androgen receptor modulators.\u003c\/p\u003e\n\u003cp\u003eThis difference creates the principal scientific value of the pairing. Researchers can investigate a recognised androgen-receptor ligand alongside a PPARδ-associated research compound while maintaining clear separation between their mechanisms.\u003c\/p\u003e\n\u003cp\u003eThe Lean Tissue \u0026amp; Metabolic Research Set name reflects these two areas of investigation rather than suggesting a predetermined combined outcome. It allows tissue-related androgen-receptor research and metabolic-signalling research to be considered within one structured comparative framework.\u003c\/p\u003e\n\u003cp\u003eBoth compounds remain individually identified 50×15mg research products intended strictly for laboratory, analytical and educational research.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eHow MK-2866 and GW-0742 Work Together\u003c\/h2\u003e\n\u003cp\u003eMK-2866 (Ostarine) and GW-0742 (Fitorine) provide a distinctive research pairing because their primary molecular pathways differ. MK-2866 is associated principally with selective androgen-receptor modulation, whereas GW-0742 is associated with PPARδ. Their scientific relationship therefore comes from the opportunity to investigate separate regulatory pathways within a broader tissue and metabolic research framework.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor targeted by MK-2866 belongs to the nuclear-receptor family and functions as a ligand-responsive regulator of gene transcription. Interaction with Ostarine can influence receptor conformation, co-regulatory interactions and downstream androgen-responsive transcription. Research has examined these processes in relation to tissue-selective signalling and lean-tissue-associated endpoints.\u003c\/p\u003e\n\u003cp\u003ePPARδ is also a nuclear receptor, but it operates through a different signalling system. Research involving PPARδ has examined transcriptional regulation associated with lipid handling, fatty-acid metabolism and cellular energy processes. GW-0742 has been used experimentally as a pharmacological tool for investigating this pathway.\u003c\/p\u003e\n\u003cp\u003ePlacing MK-2866 and GW-0742 together therefore allows two different nuclear-receptor systems to be studied within the same broader research theme. Researchers may compare predefined tissue-associated and metabolic markers while maintaining compound-specific controls.\u003c\/p\u003e\n\u003cp\u003eThe combination does not establish that the compounds are synergistic. Nor does it demonstrate that modulation of one pathway necessarily enhances the other. Cellular signalling involves interconnected biological networks, and experimental responses can vary according to concentration, exposure, receptor expression, tissue type and methodology.\u003c\/p\u003e\n\u003cp\u003eThe research value instead comes from pathway comparison. MK-2866 provides a genuine SARM and androgen-receptor research component, while GW-0742 provides a separate PPARδ-associated metabolic component.\u003c\/p\u003e\n\u003cp\u003eThis creates a structured laboratory format for examining distinct mechanisms while avoiding the scientifically incorrect classification of GW-0742 as a selective androgen receptor modulator.\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eMK-2866 (Ostarine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eMK-2866, commonly known as Ostarine and also associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator. It has become one of the more extensively investigated compounds within the SARM research field, with research extending beyond early receptor studies into controlled investigation of biological and tissue-related endpoints.\u003c\/p\u003e\n\u003cp\u003eThe principal molecular target of MK-2866 is the androgen receptor. This receptor belongs to the nuclear-receptor family and can regulate transcription of androgen-responsive genes following ligand interaction. The resulting experimental response depends upon receptor expression, cellular environment, co-regulatory proteins, exposure and the particular biological endpoint being examined.\u003c\/p\u003e\n\u003cp\u003eResearch involving Ostarine has examined tissue-selective androgen-receptor signalling alongside measurements associated with lean tissue and functional outcomes. Its comparatively developed evidence base makes it useful both as an individual experimental compound and as a reference point when investigating other research molecules.\u003c\/p\u003e\n\u003cp\u003eHowever, classification as a SARM does not mean that every claim associated with Ostarine has been established scientifically. Findings must be interpreted according to study design, research model, exposure duration and measured endpoints. Results from one experimental environment cannot automatically be transferred to another.\u003c\/p\u003e\n\u003cp\u003eWithin the Lean Tissue \u0026amp; Metabolic Research Set, MK-2866 provides the androgen-receptor-focused side of the pairing. Its established SARM classification can be considered alongside the distinctly different PPARδ-associated research profile of GW-0742.\u003c\/p\u003e\n\u003cp\u003eThis makes the combination particularly useful for comparative pathway research. Rather than studying two compounds from the same pharmacological class, researchers can examine androgen-receptor signalling and metabolic nuclear-receptor signalling separately while considering how selected experimental markers differ across the two research systems.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eGW-0742 (Fitorine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eGW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Its molecular classification is distinct from selective androgen receptor modulators and its principal research pathway should therefore not be confused with androgen-receptor signalling.\u003c\/p\u003e\n\u003cp\u003ePPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Following interaction with suitable ligands, PPAR-associated signalling can influence expression of genes involved in several areas of cellular and metabolic biology.\u003c\/p\u003e\n\u003cp\u003eResearch involving PPARδ has examined lipid handling, fatty-acid metabolism, cellular energy regulation and related transcriptional pathways. GW-0742 has been used experimentally as a pharmacological research tool for investigating receptor-associated responses and changes in predefined molecular markers.\u003c\/p\u003e\n\u003cp\u003eThe compound's inclusion alongside Ostarine is particularly useful because the two molecules represent different areas of nuclear-receptor research. Ostarine provides a selective androgen-receptor pathway, whereas GW-0742 provides a PPARδ-associated metabolic pathway.\u003c\/p\u003e\n\u003cp\u003eResearchers can therefore examine each compound independently before comparing selected endpoints within a broader tissue and metabolic research framework. This approach preserves the mechanistic differences between the molecules rather than treating commercially grouped research compounds as though they belong to the same pharmacological class.\u003c\/p\u003e\n\u003cp\u003eReceptor classification also does not guarantee a particular experimental outcome. Concentration, exposure, cellular environment, receptor expression and potential off-target activity all require consideration when interpreting findings involving GW-0742.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Lean Tissue \u0026amp; Metabolic Research Set, GW-0742 consequently provides the metabolic-signalling component of the pairing. Together with MK-2866, it supports comparative laboratory investigation of two distinct regulatory pathways while maintaining accurate scientific classification.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and metabolic research compounds from the BioPlex capsule range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-2688-ostarine-br-50x15mg\" title=\"MK-2866 Ostarine | Research SARM Capsules | BioPlex UK\"\u003eView MK-2866 Ostarine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"GW-0742 Fitorine | PPARδ Research Compound | BioPlex UK\"\u003eView GW-0742 Fitorine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/ac-262-accadrine-br-50x15mg\" title=\"AC-262 Accadrine | Research SARM Capsules | BioPlex UK\"\u003eView AC-262 Accadrine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SARMs \u0026amp; Related Research Compounds Guide 2026 | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering Ostarine MK-2866, androgen-receptor signalling, compound classification and related research pathways.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"Ostarine MK-2866 Research Overview | BioPlex Peptides\"\u003eRead the Ostarine MK-2866 Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"MK-2866 Ostarine \u0026amp; Research Compound Classification | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753428455808,"sku":null,"price":90.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MK-2866_GW-0742_dd4d94fb-1bf2-4bea-bd1b-d1caf42763e1.png?v=1787433459"},{"product_id":"rad-140-lgd-4033-yk-11","title":"RAD-140 + LGD-4033 + YK-11","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eRAD-140 (Testolone) + LGD-4033 (Ligandrol) + YK-11 (Myostine) | SARMs Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eAdvanced Myogenic Signalling Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Advanced Myogenic Signalling Research Set combines RAD-140 (Testolone) 50×15mg, LGD-4033 (Ligandrol) 50×15mg and YK-11 (Myostine) 50×15mg, providing three individually identified research compounds within a structured triple-compound format. The combination is centred on androgen-receptor biology, tissue-selective signalling and experimental investigation of molecular pathways associated with myogenic regulation.\u003c\/p\u003e\n\u003cp\u003eRAD-140 and LGD-4033 are non-steroidal selective androgen receptor modulators developed for investigation of androgen-receptor activity and tissue-selective responses. Although both interact with the same broad receptor system, differences in molecular structure and experimental history mean they should be treated as separate research compounds rather than pharmacologically interchangeable molecules.\u003c\/p\u003e\n\u003cp\u003eYK-11 introduces a substantially different element. It is frequently grouped commercially with SARMs because of its androgen-receptor-associated activity, but its steroidal structure distinguishes it from conventional non-steroidal SARMs such as RAD-140 and LGD-4033. Experimental interest in YK-11 has also extended into myogenic differentiation and follistatin-associated signalling, although its direct evidence base remains considerably more limited.\u003c\/p\u003e\n\u003cp\u003eThe Advanced Myogenic Signalling Research Set therefore brings together three compounds associated with overlapping but distinguishable areas of androgen and myogenic research.\u003c\/p\u003e\n\u003cp\u003eThe set name reflects this laboratory research theme rather than establishing a predetermined combined response. Myogenic regulation involves complex interactions between receptor signalling, transcription factors, regulatory proteins and cellular conditions.\u003c\/p\u003e\n\u003cp\u003eBy presenting all three compounds together while retaining their individual identities, BioPlex provides a comparative research format for examining conventional selective androgen-receptor modulation alongside the more specialised experimental questions associated with YK-11.\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow RAD-140, LGD-4033 and YK-11 Work Together\u003c\/h2\u003e\n\u003cp\u003eRAD-140, LGD-4033 and YK-11 share an important connection through androgen-receptor-associated research, but the scientific value of the triple set comes from their differences as much as their similarities. The androgen receptor is a ligand-responsive nuclear receptor capable of influencing gene transcription following interaction with suitable molecules.\u003c\/p\u003e\n\u003cp\u003eRAD-140 and LGD-4033 represent two structurally distinct non-steroidal selective androgen receptor modulators. Both have been investigated for their ability to interact with androgen receptors while generating tissue-dependent experimental responses. However, belonging to the same pharmacological category does not mean that their receptor interactions, concentration-response relationships or downstream transcriptional profiles are identical.\u003c\/p\u003e\n\u003cp\u003eYK-11 creates an additional research dimension. Although it demonstrates androgen-receptor-associated activity, its chemical structure differs substantially from conventional non-steroidal SARMs. Experimental cellular research has also generated interest in YK-11's relationship with myogenic differentiation and follistatin-associated expression.\u003c\/p\u003e\n\u003cp\u003eFollistatin participates in signalling involving members of the TGF-β superfamily, which has contributed to discussion of YK-11 within myostatin-related research. However, cellular observations involving follistatin should not be interpreted as proof that YK-11 directly blocks myostatin or guarantees a particular tissue response.\u003c\/p\u003e\n\u003cp\u003eThe three compounds therefore provide a framework for investigating multiple aspects of androgen-receptor and myogenic biology within one research theme. RAD-140 and LGD-4033 provide conventional non-steroidal SARM comparison points, while YK-11 introduces a structurally different androgen-receptor-associated compound with additional preliminary myogenic research interest.\u003c\/p\u003e\n\u003cp\u003eThe combination does not establish synergy between the compounds. Appropriate investigation should instead maintain compound-specific controls and distinguish receptor pharmacology, experimental observations and hypotheses requiring further evidence.\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eRAD-140 (Testolone) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eRAD-140, commonly known as Testolone, is a synthetic non-steroidal selective androgen receptor modulator developed for experimental investigation of androgen-receptor signalling and tissue-selective biological responses. Its classification places it within the genuine SARM research category alongside compounds such as LGD-4033 and MK-2866, although each molecule possesses its own chemical structure and pharmacological characteristics.\u003c\/p\u003e\n\u003cp\u003eThe androgen receptor belongs to the nuclear-receptor family and functions as a ligand-regulated transcription factor. Interaction with an appropriate ligand can alter receptor conformation and influence subsequent co-regulator recruitment, DNA interactions and expression of androgen-responsive genes.\u003c\/p\u003e\n\u003cp\u003eRAD-140 research has examined whether a non-steroidal ligand can produce selective patterns of androgen-receptor activity across different experimental tissues and models. This tissue-selectivity principle is central to the wider scientific rationale behind SARM development.\u003c\/p\u003e\n\u003cp\u003eHowever, selective does not mean that activity is restricted to a single tissue, nor does it establish a particular experimental outcome. Receptor expression, concentration, exposure duration, cellular environment and the endpoints selected for analysis can all influence observations.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Myogenic Signalling Research Set, RAD-140 provides one of the two conventional non-steroidal SARM components. Its androgen-receptor-associated research can be considered alongside LGD-4033, another structurally distinct selective androgen receptor modulator.\u003c\/p\u003e\n\u003cp\u003eYK-11 then expands the comparison beyond conventional non-steroidal SARM pharmacology by introducing a structurally different compound associated with both androgen-receptor activity and preliminary myogenic research questions.\u003c\/p\u003e\n\u003cp\u003eRAD-140 therefore contributes an important reference point for comparative androgen-receptor investigation within this three-compound set. Rather than assuming identical behaviour between all three molecules, researchers can examine compound-specific responses within a common experimental framework while retaining the individual pharmacological identity of Testolone.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eLGD-4033 (Ligandrol) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eLGD-4033, commonly known as Ligandrol, is a synthetic non-steroidal selective androgen receptor modulator developed for research into androgen-receptor signalling and tissue-selective pharmacology. It has a comparatively established research history within the SARM category and provides a useful reference compound for investigating selective androgen-receptor modulation.\u003c\/p\u003e\n\u003cp\u003eLike RAD-140, LGD-4033 interacts with the androgen receptor, a nuclear receptor capable of regulating transcription following ligand binding. However, sharing a receptor target does not make LGD-4033 and RAD-140 equivalent. Differences in molecular structure can influence receptor interaction, pharmacokinetic characteristics and experimentally observed downstream responses.\u003c\/p\u003e\n\u003cp\u003eLGD-4033 research has included controlled investigation extending beyond basic receptor-binding experiments, contributing to its position as one of the better-characterised selective androgen receptor modulators. These studies have helped researchers investigate the relationship between androgen-receptor modulation and various tissue-associated experimental endpoints.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Myogenic Signalling Research Set, LGD-4033 provides the second conventional non-steroidal SARM component. This creates a useful comparison with RAD-140 because researchers can consider two different molecules developed around the same broad principle of selective androgen-receptor modulation.\u003c\/p\u003e\n\u003cp\u003eYK-11 then provides a contrasting third component. Its steroidal structure and additional experimental interest surrounding myogenic differentiation distinguish it from both Ligandrol and Testolone.\u003c\/p\u003e\n\u003cp\u003eThe resulting research framework therefore extends beyond simply grouping three commercially recognised compounds. LGD-4033 can be investigated independently, compared directly with RAD-140 and then considered alongside the different structural and experimental characteristics of YK-11.\u003c\/p\u003e\n\u003cp\u003eThis approach preserves compound-specific interpretation while allowing the shared androgen-receptor theme connecting the three molecules to form the basis of controlled comparative laboratory research.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eYK-11 (Myostine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eYK-11, commonly referred to as Myostine within the research-compound market, is an experimental androgen-receptor-associated compound that occupies an unusual position within the wider SARM category. Although frequently grouped with selective androgen receptor modulators, its steroidal structure distinguishes it from non-steroidal compounds such as RAD-140 and LGD-4033.\u003c\/p\u003e\n\u003cp\u003eExperimental research has demonstrated androgen-receptor-associated activity, but YK-11 has attracted particular attention because of cellular research examining myogenic differentiation and follistatin-associated expression.\u003c\/p\u003e\n\u003cp\u003eFollistatin is a regulatory protein involved in biological pathways associated with members of the transforming growth factor-beta superfamily. Because this signalling network includes pathways involving myostatin, YK-11 has become widely discussed in relation to myostatin-associated research.\u003c\/p\u003e\n\u003cp\u003eThat interpretation requires significant caution. Experimental evidence showing changes in follistatin expression under specific cellular conditions does not establish that YK-11 directly inhibits myostatin or produces predetermined effects across different biological systems. Its evidence base is also much smaller than those of better-characterised SARM research compounds.\u003c\/p\u003e\n\u003cp\u003eThis makes YK-11 particularly interesting within the Advanced Myogenic Signalling Research Set. RAD-140 and LGD-4033 provide two conventional non-steroidal selective androgen receptor modulators, whereas YK-11 introduces a structurally different androgen-receptor-associated compound with additional preliminary research questions surrounding myogenic signalling.\u003c\/p\u003e\n\u003cp\u003eResearchers can therefore investigate common androgen-receptor-associated endpoints while separately considering YK-11-specific markers and hypotheses.\u003c\/p\u003e\n\u003cp\u003eYK-11 should not be treated as simply another interchangeable SARM within the set. Its structural characteristics, evidence limitations and specialised research history are precisely what differentiate it from RAD-140 and LGD-4033 and create the broader comparative value of this triple-compound research format.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related androgen-receptor and myogenic research compounds from the BioPlex SARMs capsule range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\"\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"LGD-4033 Ligandrol | Research SARM Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore LGD-4033 Ligandrol 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"YK-11 Myostine | Androgen \u0026amp; Myogenic Research Compound | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore YK-11 Myostine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products?utm_source=chatgpt.com\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering selective androgen receptor modulators, androgen-receptor signalling and related research pathways.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 Testolone Research Overview | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-140-testolone-research-overview\"\u003eRead the RAD-140 Testolone Research Overview ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"RAD-140 LGD-4033 YK-11 SARMs Research Guide | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs Research Articles | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003c\/h2\u003e\n\u003ch2\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753434845568,"sku":null,"price":125.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MaximumMyogenicResearchSet.png?v=1787397676"},{"product_id":"mk-2866-s-4-ac-262","title":"MK-2866 + S-4 \u003c\/br\u003e+ AC-262","description":"\u003ch2\u003e\u003cspan\u003eMK-2866 (Ostarine) + S-4 (Andarine) + AC-262 (Accadrine) | SARMs Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eComplete Recomposition Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Complete Recomposition Research Set combines MK-2866 (Ostarine) 50×15mg, S-4 (Andarine) 50×15mg and AC-262 (Accadrine) 50×15mg, bringing together three non-steroidal selective androgen receptor modulators within one structured laboratory research set. Each compound is supplied as an individually identified 50×15mg capsule product, allowing researchers to investigate three distinct molecules associated with androgen-receptor signalling and tissue-selective pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, is one of the better-characterised compounds within SARM research. Its scientific history includes investigation of androgen-receptor activity, tissue-selective signalling and multiple controlled biological endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4, commonly known as Andarine, represents another distinct selective androgen receptor modulator. Its development and experimental history provide a different chemical and pharmacological profile despite sharing the androgen receptor as an important molecular target.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, also identified in research literature as AC-262,536 and commonly referred to as Accadrine, introduces a third area of selective androgen-receptor investigation. Published research has examined its receptor-binding characteristics, transcriptional activity and partial-agonist behaviour.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Complete Recomposition Research Set therefore provides three different approaches to selective androgen-receptor research rather than simply presenting three interchangeable compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe set name reflects the wider tissue and body-composition-related research themes historically associated with SARM development. It does not establish or guarantee a predetermined experimental result.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eTogether, MK-2866, S-4 and AC-262 create a comparative laboratory framework for examining how structurally different androgen-receptor ligands may generate different receptor, transcriptional and tissue-dependent responses under controlled experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow MK-2866, S-4 and AC-262 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, S-4 and AC-262 share their principal scientific connection through selective androgen-receptor research. The androgen receptor belongs to the nuclear-receptor family and functions as a ligand-responsive transcriptional regulator. When an appropriate molecule interacts with the receptor, changes in receptor conformation and co-regulatory interactions can influence downstream androgen-responsive gene transcription.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe central research question behind selective androgen receptor modulators is not simply whether a compound can interact with the androgen receptor. Researchers have investigated whether structurally different ligands can generate different patterns of receptor activity and tissue-dependent response.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 provides the most extensively characterised research component of this particular set. Its comparatively developed experimental history makes it useful as a reference point when examining other selective androgen-receptor ligands.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 provides a second structurally distinct SARM. Its individual pharmacological characteristics allow researchers to compare another androgen-receptor ligand against the Ostarine research framework rather than assuming all compounds within the SARM category behave identically.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 adds a particularly interesting third comparison because published research has associated it with partial-agonist characteristics. Partial agonism can produce a different maximal receptor response from full agonism under comparable experimental conditions, making receptor activation an important area for comparative investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePlacing the three compounds within one research framework therefore allows researchers to examine receptor interaction, transcriptional signalling and predefined tissue-associated markers across three separate molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination does not establish synergy between MK-2866, S-4 and AC-262. Nor should findings involving one compound automatically be transferred to another.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value instead lies in controlled comparison: three non-steroidal androgen-receptor ligands, three distinct chemical structures and three separate evidence profiles examined within a common selective androgen-receptor research theme.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-2866 (Ostarine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator with one of the more developed research histories within the SARM category.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts principal molecular target is the androgen receptor. This receptor belongs to the nuclear-receptor superfamily and can influence transcription of androgen-responsive genes following interaction with suitable ligands. The resulting biological response can depend upon receptor expression, cellular environment, co-regulatory proteins, exposure and the experimental endpoint being measured.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving Ostarine has extended beyond early receptor-binding studies into controlled investigation of tissue-related and functional endpoints. This comparatively broad evidence base makes MK-2866 particularly useful when researchers require a recognised SARM against which other androgen-receptor ligands can be compared.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe term selective remains important. Selective androgen receptor modulation does not mean that a compound acts exclusively within one tissue. Rather, SARM research has investigated whether different ligands can generate differing patterns of androgen-receptor-associated activity across experimental tissues and systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Complete Recomposition Research Set, MK-2866 provides the established reference component. Researchers can compare its receptor and tissue-associated profile with S-4 Andarine and AC-262 Accadrine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis comparison is particularly relevant because all three compounds share a broad pharmacological classification while remaining chemically distinct molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe existence of a more developed evidence base also does not mean that every claim associated with Ostarine has been scientifically established. Findings must always be interpreted according to the study design, model, exposure and endpoints used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 therefore provides a well-characterised foundation for comparative selective androgen-receptor investigation within this three-compound research format.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eS-4 (Andarine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4, commonly known as Andarine, is a synthetic non-steroidal selective androgen receptor modulator developed during research into tissue-selective androgen-receptor pharmacology. It belongs to the genuine SARM research category and provides a second structurally distinct androgen-receptor ligand within the Complete Recomposition Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor acts as a ligand-regulated transcription factor. Interaction with different ligands can alter receptor conformation and influence subsequent interactions with cellular co-regulators and androgen-responsive DNA elements.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis provides an important basis for comparative SARM research. Two compounds interacting with the same receptor do not necessarily generate identical pharmacological profiles or downstream experimental responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 has been investigated within preclinical selective androgen-receptor research and has contributed to broader understanding of how non-steroidal ligands may produce different patterns of activity across experimental systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin this triple set, Andarine provides an intermediate comparison between MK-2866 and AC-262. Ostarine brings a comparatively developed research history, while AC-262 introduces published interest surrounding partial-agonist characteristics. S-4 contributes another independent non-steroidal androgen-receptor ligand with its own molecular and experimental profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore examine predefined receptor-associated and tissue-dependent endpoints across all three compounds while maintaining individual controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-4 should not be treated as interchangeable with Ostarine or AC-262 simply because all three belong to the SARM category. Chemical structure, receptor interaction, concentration, exposure and experimental conditions can materially influence observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts role within the Complete Recomposition Research Set is therefore comparative: providing another recognised selective androgen-receptor research compound against which the characteristics of MK-2866 and AC-262 can be independently evaluated.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eAC-262 (Accadrine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, commonly known as Accadrine and identified scientifically as AC-262,536, is a synthetic non-steroidal selective androgen receptor modulator investigated through receptor-binding, transcriptional and preclinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eOne of the most interesting aspects of AC-262 research concerns its reported partial-agonist characteristics at the androgen receptor. A partial agonist can interact with a receptor while producing a lower maximal response than a full agonist under comparable experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis makes AC-262 particularly relevant to comparative SARM research because receptor binding alone does not determine the complete experimental response. Ligand structure, receptor conformation, co-regulatory interactions, receptor density and cellular environment can all influence downstream activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePublished AC-262 research has examined androgen-receptor binding and tissue-selective experimental responses, although its evidence base is considerably smaller than that surrounding more extensively investigated compounds such as Ostarine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Complete Recomposition Research Set, this difference becomes useful rather than problematic. MK-2866 provides a comparatively established SARM reference, S-4 provides another recognised non-steroidal androgen-receptor ligand, and AC-262 introduces a molecule particularly associated with partial-agonist research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore investigate whether three structurally different compounds within the same broad pharmacological category produce different receptor-associated and transcriptional observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 should not be treated as equivalent to either Ostarine or Andarine. Each compound requires independent experimental interpretation and appropriate compound-specific controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion consequently expands the research value of the set beyond simply increasing the number of SARMs being examined. AC-262 adds a distinct pharmacological question concerning receptor activation and partial agonism to the broader selective androgen-receptor research framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring selective androgen receptor modulators from the BioPlex SARMs capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-2688-ostarine-br-50x15mg\" title=\"MK-2866 Ostarine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-2866 Ostarine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"S-4 Andarine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eExplore S-4 Andarine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/ac-262-accadrine-br-50x15mg\" title=\"AC-262 Accadrine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView AC-262 Accadrine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering Ostarine, AC-262, selective androgen-receptor signalling and comparative SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/de\/blogs\/sarms-research-articles-bioplex-peptides-uk\/h1-science-research-studies-ac-262-vs-ostarine-mk-2866-androgen-receptor-research-compared\" title=\"AC-262 vs Ostarine MK-2866 | Androgen Receptor Research | BioPlex Peptides\"\u003e\u003cspan\u003eRead AC-262 vs Ostarine MK-2866: Androgen-Receptor Research Compared ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"MK-2866 S-4 AC-262 SARMs Research Guide | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753551040896,"sku":null,"price":136.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/CompleteRecompositionResearchSet-MK-2866.png?v=1787397834"},{"product_id":"sr-9009-sr-9011-gw-0742","title":"SR-9009 + SR-9011 + GW-0742","description":"\u003cdiv class=\"qMYqUG_convSearchResultHighlightRoot\"\u003e\n\u003cdiv class=\"\"\u003e\n\u003csection class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [\u0026amp;:has([data-writing-block])\u0026gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\"\u003e\n\u003cdiv class=\"text-base my-auto mx-auto pb-8 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\"\u003e\n\u003cdiv class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\"\u003e\n\u003cdiv class=\"flex max-w-full flex-col gap-4 grow\"\u003e\n\u003cdiv dir=\"auto\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+\u0026amp;]:mt-1\" tabindex=\"0\"\u003e\n\u003cdiv class=\"flex w-full flex-col gap-1 empty:hidden\"\u003e\n\u003cdiv class=\"markdown prose dark:prose-invert wrap-break-word w-full dark markdown-new-styling\"\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eSR-9009 (Stenabolic) + SR-9011 (REV-ERB Agonist) + GW-0742 (Fitorine) | Metabolic Research UK\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003eAdvanced Metabolic Activity Research Set\u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Advanced Metabolic Activity Research Set combines SR-9009 (Stenabolic) 50×15mg, SR-9011 (REV-ERB Agonist) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together three synthetic research compounds associated with nuclear-receptor signalling, circadian regulation and metabolic research. The set contains one pot of each compound and provides a structured triple-compound format for comparative laboratory investigation across two distinct areas of molecular signalling.\u003c\/p\u003e\n\u003cp\u003eSR-9009 and SR-9011 are closely associated with research involving REV-ERBα and REV-ERBβ. These nuclear receptors participate in transcriptional networks connecting the molecular circadian clock with metabolic regulation. Synthetic ligands associated with REV-ERB research have consequently been investigated across experimental models examining circadian gene expression, metabolic signalling and related cellular processes.\u003c\/p\u003e\n\u003cp\u003eGW-0742 provides a different molecular pathway. The compound is primarily associated with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. This nuclear receptor participates in transcriptional pathways involving lipid handling, fatty-acid metabolism and cellular-energy regulation.\u003c\/p\u003e\n\u003cp\u003eImportantly, none of these three compounds is scientifically classified as a selective androgen receptor modulator. Their inclusion within broader research-compound categories should not be confused with androgen-receptor pharmacology.\u003c\/p\u003e\n\u003cp\u003eThe Advanced Metabolic Activity Research Set therefore creates a multi-pathway research framework rather than combining three compounds with an identical molecular target.\u003c\/p\u003e\n\u003cp\u003eThe set name reflects their shared relevance to experimental metabolic research and does not establish a predetermined combined response. Each compound retains its own molecular identity, evidence profile and research limitations, allowing REV-ERB-associated and PPARδ-associated signalling to be investigated independently and comparatively.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eHow SR-9009, SR-9011 and GW-0742 Work Together\u003c\/h2\u003e\n\u003cp\u003eSR-9009, SR-9011 and GW-0742 create a particularly interesting research combination because the three compounds connect two separate nuclear-receptor systems with broader metabolic and transcriptional biology. SR-9009 and SR-9011 are associated with REV-ERB research, while GW-0742 provides a separate PPARδ-associated pathway.\u003c\/p\u003e\n\u003cp\u003eREV-ERBα and REV-ERBβ form part of the molecular machinery connecting circadian timing with transcriptional regulation. Experimental research involving synthetic REV-ERB ligands has examined how pharmacological manipulation of these pathways corresponds with changes in metabolic gene expression, cellular-energy processes and other predefined biological markers.\u003c\/p\u003e\n\u003cp\u003eSR-9009 and SR-9011 provide two related but individually distinct compounds for investigating this area. Their relationship does not mean their pharmacological behaviour is necessarily identical. Differences in molecular structure, concentration-response relationships, cellular exposure and potential off-target activity can influence experimental observations.\u003c\/p\u003e\n\u003cp\u003eGW-0742 expands the research framework through PPARδ. PPARδ belongs to the nuclear-receptor superfamily but operates through a distinct regulatory system associated with expression of genes involved in lipid and fatty-acid metabolism and broader cellular-energy processes.\u003c\/p\u003e\n\u003cp\u003eThe three compounds therefore allow REV-ERB-associated observations to be considered alongside PPARδ-associated observations within a common metabolic research theme.\u003c\/p\u003e\n\u003cp\u003eThis does not establish synergy. It would be scientifically inappropriate to assume that simultaneous investigation of these pathways automatically produces an enhanced metabolic response. The interaction between transcriptional systems is complex and dependent upon experimental model, receptor expression, concentration and methodology.\u003c\/p\u003e\n\u003cp\u003eThe value of this triple set instead lies in comparative pathway investigation: two related REV-ERB research compounds alongside a distinct PPARδ research compound, providing a broader framework for controlled investigation of metabolic and nuclear-receptor signalling.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eSR-9009 (Stenabolic) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9009, commonly known as Stenabolic, is a synthetic research compound developed during investigation of the nuclear receptors REV-ERBα and REV-ERBβ. Although frequently grouped commercially alongside SARMs, SR-9009 is not a selective androgen receptor modulator and should not be described as operating principally through androgen-receptor signalling.\u003c\/p\u003e\n\u003cp\u003eREV-ERB receptors participate in transcriptional networks linking circadian regulation with metabolic processes. These receptors form part of the molecular machinery governing rhythmic gene expression and have consequently attracted research interest in relation to metabolic biology.\u003c\/p\u003e\n\u003cp\u003eEarly experimental research involving SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could correspond with changes in measurable circadian and metabolic endpoints. This generated interest in metabolic gene expression, mitochondrial-associated processes, energy regulation and other related cellular markers.\u003c\/p\u003e\n\u003cp\u003eHowever, the mechanistic interpretation of SR-9009 requires caution. Later experimental research has reported SR-9009-associated effects in systems where functional REV-ERB activity was absent or disrupted. These observations suggest that some effects associated with SR-9009 may occur through mechanisms that are not exclusively dependent upon REV-ERB.\u003c\/p\u003e\n\u003cp\u003eAn observed experimental response following SR-9009 exposure therefore should not automatically be considered proof of direct REV-ERB-mediated activity.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Metabolic Activity Research Set, SR-9009 provides one of two REV-ERB-associated research components. SR-9011 provides a related compound for comparison, while GW-0742 introduces the separate PPARδ pathway.\u003c\/p\u003e\n\u003cp\u003eThis three-way structure enables SR-9009 findings to be interpreted within a broader metabolic research framework while retaining appropriate compound-specific controls and distinguishing observed responses from conclusions about precise molecular mechanisms.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eSR-9011 (REV-ERB Agonist) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9011 is a synthetic research compound developed within the broader investigation of REV-ERBα and REV-ERBβ nuclear receptors. It is commonly described within experimental literature as a synthetic REV-ERB ligand or agonist and has been investigated in connection with circadian signalling, transcriptional regulation and metabolic biology.\u003c\/p\u003e\n\u003cp\u003eREV-ERB receptors participate in the molecular circadian system and contribute to networks regulating rhythmic gene expression. Their relationship with metabolic pathways has made them important experimental targets for researchers investigating the connection between biological timing and cellular metabolism.\u003c\/p\u003e\n\u003cp\u003eSR-9011 provides a second synthetic compound associated with this receptor system alongside SR-9009. Although their research histories overlap, the two molecules should remain individually identified. Structurally related compounds can differ in receptor interaction, concentration-response characteristics, cellular availability and potential off-target behaviour.\u003c\/p\u003e\n\u003cp\u003eThis distinction is particularly important within comparative research. Results obtained with SR-9009 cannot automatically be transferred to SR-9011, even where both compounds are investigated under a common REV-ERB-associated research theme.\u003c\/p\u003e\n\u003cp\u003eSR-9011 is also not a SARM. Its principal research classification concerns REV-ERB-associated nuclear-receptor biology rather than selective modulation of the androgen receptor.\u003c\/p\u003e\n\u003cp\u003eWithin the Advanced Metabolic Activity Research Set, SR-9011 provides the second REV-ERB-focused component. Researchers can compare its experimental characteristics with SR-9009 before considering observations alongside the distinctly different PPARδ-associated profile of GW-0742.\u003c\/p\u003e\n\u003cp\u003eThis arrangement provides a broader laboratory framework for examining metabolic transcriptional signalling without treating three separate compounds as pharmacologically interchangeable.\u003c\/p\u003e\n\u003cp\u003eSR-9011 consequently contributes both a direct comparison point for SR-9009 and a contrasting research pathway when considered alongside GW-0742.\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eGW-0742 (Fitorine) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eGW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Its molecular classification is distinct from both selective androgen receptor modulators and the REV-ERB-associated compounds included elsewhere in this set.\u003c\/p\u003e\n\u003cp\u003ePPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Research involving this receptor has examined pathways associated with lipid handling, fatty-acid metabolism, cellular-energy regulation and expression of metabolically relevant genes.\u003c\/p\u003e\n\u003cp\u003eGW-0742 has consequently been used experimentally as a pharmacological research tool for investigating PPARδ-associated signalling and determining how receptor modulation corresponds with changes in predefined molecular and cellular endpoints.\u003c\/p\u003e\n\u003cp\u003eIts inclusion within the Advanced Metabolic Activity Research Set expands the scientific scope beyond the REV-ERB pathway represented by SR-9009 and SR-9011.\u003c\/p\u003e\n\u003cp\u003eRather than studying three compounds directed toward one receptor family, researchers can examine two related REV-ERB-associated compounds and compare their observations with a separate PPARδ-associated experimental pathway.\u003c\/p\u003e\n\u003cp\u003eGW-0742 should therefore not be described as possessing the same mechanism as SR-9009 or SR-9011. Nor does the inclusion of all three compounds establish a synergistic interaction.\u003c\/p\u003e\n\u003cp\u003eExperimental responses involving GW-0742 depend upon factors including receptor expression, compound concentration, exposure, cellular environment and methodology. Potential off-target activity and model-specific findings should also be considered when interpreting results.\u003c\/p\u003e\n\u003cp\u003eWithin this triple research set, GW-0742 provides the PPARδ-focused component and creates the multi-pathway aspect of the combination. Together, the three compounds support comparative investigation of distinct nuclear-receptor systems associated with metabolic and cellular-energy research.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related metabolic and nuclear-receptor research compounds from the BioPlex range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SR-9009 Stenabolic | Metabolic Research Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eView SR-9009 Stenabolic 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SR-9011 REV-ERB Agonist | Metabolic Research Capsules | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eView SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"GW-0742 Fitorine | PPARδ Research Compound | BioPlex UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eView GW-0742 Fitorine 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003ch3\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs \u0026amp; Related Research Compounds Guide 2026 | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs \u0026amp; Research Compounds UK | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms?utm_source=chatgpt.com\"\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products?utm_source=chatgpt.com\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering metabolic research compounds, nuclear-receptor signalling and the scientific classification of compounds sold alongside SARMs.\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SR-9009 SR-9011 GW-0742 Research Compound Classification | BioPlex Peptides\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026?utm_source=chatgpt.com\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk?utm_source=chatgpt.com\"\u003eExplore BioPlex SARMs \u0026amp; Research Compound Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753631060352,"sku":null,"price":136.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/AdvancedMetabolicActivityResearchSet_3.png?v=1787397348"},{"product_id":"lgd-4033-mk-677-mk-777","title":"LGD-4033 + MK-677 + MK-777","description":"\u003ch2\u003e\u003cspan\u003eLGD-4033 (Ligandrol) + MK-677 (Ibutamoren) + MK-777 (Acetamoren) | SARMs \u0026amp; Growth-Factor Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eAndrogen \u0026amp; Growth-Factor Signalling Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Androgen \u0026amp; Growth-Factor Signalling Research Set combines LGD-4033 (Ligandrol) 50×15mg, MK-677 (Ibutamoren) 50×15mg and MK-777 (Acetamoren) 50×15mg, creating a three-compound research format spanning selective androgen-receptor signalling and growth-hormone-secretagogue-associated research. The set contains one pot of each compound and is designed around comparative investigation of different molecular pathways rather than treating all three compounds as pharmacologically identical.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 is a genuine non-steroidal selective androgen receptor modulator. Its research history centres on androgen-receptor binding, tissue-selective signalling and downstream androgen-responsive pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 belongs to a fundamentally different pharmacological category. Also known as Ibutamoren, it is a non-peptide growth hormone secretagogue and established agonist of the ghrelin receptor, GHS-R1a. Research involving MK-677 has examined growth-hormone secretion, downstream IGF-1-associated signalling and broader endocrine and metabolic variables.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly known as Acetamoren, provides the third component. It is an emerging small-molecule research compound frequently positioned alongside MK-677 within the research market. However, its direct compound-specific evidence remains substantially less developed than the evidence available for Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Androgen \u0026amp; Growth-Factor Signalling Research Set therefore brings together one established androgen-receptor pathway with two compounds associated commercially with growth-hormone-secretagogue research, while maintaining appropriate distinction between their respective evidence levels.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe name reflects the scientific pathways represented within the set rather than guaranteeing a particular combined outcome. Each compound remains independently identified, enabling researchers to separate established pharmacology from newer hypotheses while examining multiple signalling systems within one structured research framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow LGD-4033, MK-677 and MK-777 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033, MK-677 and MK-777 create a multi-pathway research combination because they are associated with different areas of molecular and endocrine signalling. The principal distinction is between LGD-4033's established androgen-receptor activity and the growth-hormone-secretagogue-associated research surrounding MK-677 and MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 interacts with the androgen receptor, a ligand-regulated nuclear receptor involved in androgen-responsive transcription. As a non-steroidal selective androgen receptor modulator, Ligandrol has been investigated to determine how synthetic ligands can influence androgen-receptor activity and generate tissue-dependent experimental responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677 operates through a different established pathway. Ibutamoren is an agonist of the growth hormone secretagogue receptor, commonly called GHS-R1a or the ghrelin receptor. Activation of this receptor has been investigated in relation to growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 is frequently associated with a similar commercial research category to MK-677, but the evidence surrounding Acetamoren is considerably thinner. It should therefore not automatically be assumed to possess identical receptor affinity, signalling characteristics or downstream activity to Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis makes the triple set useful for comparative pathway investigation. LGD-4033 provides a clearly characterised androgen-receptor component, MK-677 provides an established ghrelin-receptor and growth-hormone-secretagogue component, and MK-777 introduces an emerging compound requiring more cautious experimental interpretation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination itself does not establish synergy between the three compounds. Nor should evidence involving LGD-4033 or MK-677 automatically be transferred to MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value instead lies in examining different signalling pathways within a common research framework while maintaining compound-specific controls, appropriate analytical identification and clear separation between established findings and emerging research hypotheses.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eLGD-4033 (Ligandrol) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033, commonly known as Ligandrol and also associated with the developmental identifier VK5211, is a synthetic non-steroidal selective androgen receptor modulator. It represents the androgen-receptor-focused component of the BioPlex Androgen \u0026amp; Growth-Factor Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor belongs to the nuclear-receptor superfamily and functions as a ligand-regulated transcription factor. Interaction between an appropriate ligand and the receptor can alter receptor conformation, co-regulator recruitment and subsequent expression of androgen-responsive genes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 has been investigated as a high-affinity androgen-receptor ligand and forms part of the broader scientific effort to understand whether non-steroidal compounds can generate tissue-selective patterns of androgen-receptor activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts research history is substantially different from that of MK-677. Although both compounds are frequently sold within commercial SARMs categories, MK-677 does not primarily interact with the androgen receptor and should not be classified as a SARM.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction makes LGD-4033 particularly valuable within this three-compound set. It establishes a clearly defined androgen-receptor research pathway against which the different endocrine-signalling research surrounding MK-677 can be considered.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 introduces a further research question because its compound-specific evidence base remains much less developed.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers should therefore avoid treating the three molecules as interchangeable or assuming that their placement within one set means they share the same mechanism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Androgen \u0026amp; Growth-Factor Signalling Research Set, LGD-4033 provides the established SARM component. Its receptor pharmacology, tissue-selective research history and androgen-responsive endpoints can be examined independently while researchers separately investigate growth-hormone-secretagogue-associated pathways represented by the other compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis creates a broader comparative research framework than a set containing three molecules targeting only the androgen receptor.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eMK-677 (Ibutamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-677, commonly known as Ibutamoren and also identified as MK-0677 or L-163,191, is a synthetic non-peptide growth hormone secretagogue. Unlike LGD-4033, MK-677 is not a selective androgen receptor modulator and does not derive its principal research activity from androgen-receptor signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts established molecular target is the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor. Ghrelin acts as an endogenous ligand within this receptor system, while MK-677 has been investigated as a synthetic agonist capable of activating ghrelin-receptor-associated signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving Ibutamoren has examined growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1. Experimental research has also explored appetite-associated signalling, metabolic variables, sleep-related measurements, body-composition endpoints and other physiological processes associated with the broader ghrelin and growth-hormone signalling systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis relatively developed research history makes MK-677 useful as the established growth-hormone-secretagogue component of this triple set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion alongside LGD-4033 creates a clear mechanistic contrast. Ligandrol provides selective androgen-receptor modulation, whereas Ibutamoren provides ghrelin-receptor agonism and growth-hormone-secretagogue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 then provides an emerging third comparison associated commercially with related research themes but supported by a much smaller direct evidence base.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Androgen \u0026amp; Growth-Factor Signalling Research Set, MK-677 should therefore be considered independently rather than being grouped pharmacologically with LGD-4033 simply because both compounds appear within the wider BioPlex capsule research range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts established receptor classification provides researchers with a defined molecular pathway that can be investigated alongside androgen-receptor signalling while retaining separate experimental controls and endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction supports more accurate comparative research and prevents commercial product categorisation from being mistaken for scientific classification.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-777 (Acetamoren) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777, commonly referred to as Acetamoren, is an emerging synthetic small-molecule research compound that has increasingly appeared within research-compound catalogues alongside MK-677 Ibutamoren and compounds commercially grouped within SARMs ranges.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe available evidence surrounding MK-777 requires substantially greater caution than the evidence available for either LGD-4033 or MK-677.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLGD-4033 possesses an established research classification as a selective androgen receptor modulator, while MK-677 has a documented pharmacological relationship with the growth hormone secretagogue receptor GHS-R1a. MK-777 does not currently possess an equivalent publicly accessible body of compound-specific pharmacological research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAcetamoren is frequently positioned commercially within growth-hormone-secretagogue-associated research and compared with MK-677. However, commercial classification or naming similarity should not be treated as proof that MK-777 possesses identical receptor affinity, potency, pharmacokinetics or downstream signalling behaviour to Ibutamoren.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis evidence distinction is particularly important within the Androgen \u0026amp; Growth-Factor Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-777 provides an emerging research component that can be considered alongside two better-characterised reference compounds. LGD-4033 establishes the androgen-receptor pathway, while MK-677 establishes the recognised ghrelin-receptor and growth-hormone-secretagogue pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers investigating MK-777 can therefore distinguish observations involving Acetamoren from the established pharmacology of the other compounds rather than transferring findings from MK-677 directly onto MK-777.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific value of MK-777 within this combination consequently comes partly from the unanswered questions surrounding its classification and molecular activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eCareful compound identification, appropriate experimental controls and independent interpretation remain particularly important. This allows emerging MK-777 research to develop without overstating the current evidence or presenting proposed mechanisms as though they were already established pharmacological facts.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related androgen-receptor and growth-hormone-secretagogue research compounds from the BioPlex capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/lgd-4033-ligandrol-br-50x15mg\" title=\"LGD-4033 Ligandrol | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView LGD-4033 Ligandrol 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-677-ibutamoren-br-50x15mg\" title=\"MK-677 Ibutamoren | Growth Hormone Secretagogue Research | BioPlex UK\"\u003e\u003cspan\u003eView MK-677 Ibutamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-777-acetamoren-br-50x15mg\" title=\"MK-777 Acetamoren | Research Compound Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-777 Acetamoren 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Related Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering LGD-4033, MK-677, MK-777, androgen-receptor activity and growth-hormone-secretagogue research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-677-ibutamoren-research-overview\" title=\"MK-677 Ibutamoren Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-677 Ibutamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/mk-777-acetamoren-research-overview-research-studies\" title=\"MK-777 Acetamoren Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the MK-777 Acetamoren Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-mk-777-vs-mk-677-compound-classification-research-pathways-and-key-differences\" title=\"MK-777 vs MK-677 | Research Pathways \u0026amp; Key Differences | BioPlex Peptides\"\u003e\u003cspan\u003eRead MK-777 vs MK-677: Research Pathways \u0026amp; Key Differences ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753852080512,"sku":null,"price":130.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/MK-677_LGD-4033_MK-777.png?v=1787433697"},{"product_id":"rad-140-rad-150-s-23","title":"RAD-140 + RAD-150 + S-23","description":"\u003ch2\u003e\u003cspan\u003eRAD-140 (Testolone) + RAD-150 (TLB-150) + S-23 (Mastorin) | SARMs Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eAdvanced Androgen Signalling Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Advanced Androgen Signalling Research Set combines RAD-140 (Testolone) 50×15mg, RAD-150 (TLB-150) 50×15mg and S-23 (Mastorin) 50×15mg, bringing together three research compounds associated with selective androgen-receptor signalling within one structured laboratory research set. The set contains one pot of each compound and provides a comparative framework for examining three chemically distinct molecules associated with androgen-receptor research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140 is a non-steroidal selective androgen receptor modulator developed for investigation of tissue-selective androgen-receptor activity. Its research history makes Testolone one of the better recognised compounds within the modern SARM research category and provides an important reference point within this combination.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-150, commonly identified as TLB-150, is positioned as a RAD-140-related research compound. Its relationship with Testolone makes it particularly interesting for comparative investigation, although the direct published evidence available specifically for RAD-150 remains considerably more limited than that surrounding RAD-140. Claims concerning differences in potency, duration or biological activity should therefore be treated as research hypotheses rather than automatically established facts.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 provides the third androgen-receptor-associated component. It is a non-steroidal SARM with its own experimental history involving androgen-receptor activity and tissue-associated responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Advanced Androgen Signalling Research Set therefore provides three separate compounds for investigating a common molecular research theme without assuming that their pharmacological behaviour is identical.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts name reflects the focus on androgen-receptor signalling rather than guaranteeing any predetermined experimental outcome. Each compound remains independently identified, allowing differences in molecular structure, receptor activity and experimental evidence to be examined under controlled laboratory conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow RAD-140, RAD-150 and S-23 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140, RAD-150 and S-23 are grouped within the Advanced Androgen Signalling Research Set because each is associated with androgen-receptor research. However, the scientific value of the combination lies in comparing their individual characteristics rather than assuming that three androgen-receptor-associated compounds automatically produce the same biological responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor belongs to the nuclear-receptor superfamily and functions as a ligand-responsive transcription factor. Interaction with a suitable ligand can alter receptor conformation and influence co-regulatory interactions and downstream expression of androgen-responsive genes. Selective androgen receptor modulators were developed partly to investigate whether different non-steroidal ligands could generate different patterns of activity across experimental tissues.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140 provides an established non-steroidal SARM research component. Its experimental history creates a useful reference for studying selective androgen-receptor signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-150 provides a closely related but much less extensively characterised comparison. Its association with RAD-140 makes structural and analytical comparison particularly relevant, while its limited direct evidence means conclusions concerning its exact pharmacological profile require caution.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 expands the research framework through another structurally distinct selective androgen receptor modulator. Researchers can investigate its receptor-associated behaviour independently before comparing predefined experimental endpoints with RAD-140 and RAD-150.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination itself does not establish synergy between the three compounds. Nor should research findings involving RAD-140 automatically be transferred to RAD-150 or S-23. Receptor affinity, cellular environment, concentration, exposure and compound-specific characteristics can all influence observations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe set instead provides a structured three-way comparison: an established Testolone research compound, a closely related RAD-150 compound with a developing evidence base and a separate S-23 SARM reference. This enables advanced comparative investigation of androgen-receptor signalling while maintaining compound-specific controls and evidence-based interpretation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eRAD-140 (Testolone) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140, commonly known as Testolone, is a synthetic non-steroidal selective androgen receptor modulator developed for experimental investigation of androgen-receptor signalling and tissue-selective responses. It belongs to the genuine SARM research category and provides the principal reference compound within the Advanced Androgen Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor is a ligand-responsive nuclear receptor capable of influencing transcription following interaction with appropriate molecules. When a ligand interacts with the receptor, changes in receptor conformation and subsequent co-regulatory interactions can influence expression of androgen-responsive genes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140 research has focused on whether non-steroidal androgen-receptor ligands can demonstrate tissue-dependent patterns of activity. This concept of selective receptor modulation forms an important part of the scientific rationale behind SARM development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSelective should not, however, be interpreted as meaning that RAD-140 acts exclusively within one tissue or produces a guaranteed experimental response. Receptor expression, concentration, cellular environment, exposure and experimental design can influence observed activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin this triple research set, RAD-140 is particularly useful because RAD-150 is positioned as a closely related compound. This provides researchers with an opportunity to distinguish the comparatively better-established research profile of Testolone from claims and hypotheses surrounding the less extensively characterised TLB-150.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 then provides a third structurally distinct androgen-receptor ligand for comparison.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-140 therefore forms an important reference point across the combination. Researchers can examine its established androgen-receptor-associated characteristics independently before comparing selected molecular or cellular endpoints with RAD-150 and S-23.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis approach maintains the identity of each compound and prevents the shared SARM category from being interpreted as evidence that all three molecules possess identical receptor behaviour or downstream experimental profiles.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eRAD-150 (TLB-150) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-150, commonly identified as TLB-150, is a research compound closely associated with RAD-140 Testolone and frequently grouped within the selective androgen receptor modulator research category. Its relationship with RAD-140 makes it particularly relevant within this triple set, but its evidence base requires more cautious interpretation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRAD-150 is commonly described within the research-compound market as a RAD-140-related or modified research molecule. However, the amount of accessible direct published pharmacological research specifically examining RAD-150 is considerably smaller than the evidence available for RAD-140.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis distinction is important because claims concerning a compound's potency, duration, receptor activity or experimental performance require compound-specific evidence. Characteristics demonstrated for RAD-140 should not automatically be assumed to apply to RAD-150 simply because the two compounds are chemically or commercially associated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Advanced Androgen Signalling Research Set, this evidence difference creates a useful comparative research question. RAD-140 provides the better-characterised Testolone reference, while RAD-150 provides a related molecule whose analytical and pharmacological characteristics can be investigated independently.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 then provides a third SARM research compound that is not part of the RAD series, allowing researchers to extend comparison beyond closely related molecules.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearch involving RAD-150 should therefore maintain appropriate compound identification and independent experimental controls. Observed responses need to be attributed to RAD-150 itself rather than inferred from Testolone research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion within this set is particularly valuable for investigating similarities and differences between compounds positioned within the same broader androgen-receptor research category.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eRather than presenting RAD-150 as simply a stronger or longer-lasting version of RAD-140, the BioPlex research approach maintains the distinction between established evidence and claims requiring further experimental validation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eS-23 (Mastorin) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23, presented within the BioPlex research range as Mastorin, is a synthetic non-steroidal selective androgen receptor modulator investigated for its interaction with androgen receptors and associated tissue-dependent experimental responses. It provides the third distinct SARM component within the Advanced Androgen Signalling Research Set.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eLike RAD-140, S-23 belongs to the broader category of non-steroidal androgen-receptor ligands developed to investigate selective receptor modulation. However, classification within the same category does not mean that S-23 and RAD-140 are pharmacologically interchangeable.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eDifferent molecular structures can influence receptor affinity, receptor conformation, co-regulatory interactions, concentration-response relationships and downstream transcriptional activity. These differences form an important part of comparative SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 has an experimental history involving androgen-receptor-associated activity and reproductive-endocrine research models. This provides a distinct evidence profile from RAD-140 and an even clearer distinction from the considerably less characterised RAD-150.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin this triple set, S-23 therefore broadens the comparison. RAD-140 provides an established Testolone reference, RAD-150 provides a closely related but less extensively studied research compound, and S-23 provides an independently developed selective androgen receptor modulator.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can examine S-23-specific responses before comparing predefined endpoints across all three compounds. This may include receptor-associated, transcriptional or other experimentally appropriate measurements selected according to the laboratory model being used.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe presence of three androgen-receptor-associated compounds does not itself establish a combined or synergistic response. Compound concentration, exposure, receptor expression and experimental conditions remain critical variables.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eS-23 consequently contributes an independent androgen-receptor research pathway to the combination, allowing the Advanced Androgen Signalling Research Set to support broader comparative investigation rather than simply comparing the two closely associated RAD compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related selective androgen receptor modulators from the BioPlex SARMs capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/rad-140-tesolone-br-50x15mg\" title=\"RAD-140 Testolone | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView RAD-140 Testolone 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"RAD-150 TLB-150 | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eExplore RAD-150 TLB-150 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"S-23 Mastorin | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eExplore S-23 Mastorin 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering RAD-140 Testolone, RAD-150 TLB-150, selective androgen-receptor signalling and related SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-140-testolone-research-overview\" title=\"RAD-140 Testolone Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the RAD-140 Testolone Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/rad-150-tlb-150-research-overview\" title=\"RAD-150 TLB-150 Research Overview | BioPlex Peptides\"\u003e\u003cspan\u003eRead the RAD-150 TLB-150 Research Overview ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753866563968,"sku":null,"price":130.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/RAD-140_RAD-150_S-23_aefa5d51-5072-4c76-a376-4d7d4760178d.png?v=1787434549"},{"product_id":"mk-2866-ac-262-acp-105","title":"MK-2866 + AC-262 \u003c\/br\u003e+ACP-105","description":"\u003ch2\u003e\n\u003cspan\u003eACP-105 (Androxepen) + \u003c\/span\u003e\u003cspan\u003eMK-2866 (Ostarine) + AC-262 (Accadrine) + | SARMs Research UK\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eSelective Androgen Pathway Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Selective Androgen Pathway Research Set combines MK-2866 (Ostarine) 50×15mg, AC-262 (Accadrine) 50×15mg and ACP-105 (Androxepen) 50×15mg, bringing together three non-steroidal selective androgen receptor modulators within one structured laboratory research set. Each compound is individually identified, allowing researchers to compare three different molecules associated with selective androgen-receptor signalling while maintaining compound-specific experimental controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, provides the most extensively characterised component of the combination. Its research history extends from androgen-receptor pharmacology into controlled investigation of tissue-associated and functional endpoints, making it a useful reference compound within comparative SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, also identified scientifically as AC-262,536 and commonly called Accadrine, provides a different selective androgen-receptor profile. Research has examined its receptor binding and partial-agonist characteristics, creating an interesting comparison with better-characterised SARMs such as Ostarine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eACP-105, presented by BioPlex as Androxepen, introduces a third non-steroidal androgen-receptor research compound. Its experimental history is smaller than that surrounding MK-2866, but preclinical research has investigated its selective androgen-receptor activity and tissue-dependent pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Selective Androgen Pathway Research Set therefore provides three distinct approaches to a common molecular research theme rather than treating all SARMs as interchangeable compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe set name reflects this shared androgen-receptor pathway without implying a predetermined experimental outcome. Differences in molecular structure, receptor interaction, transcriptional activity and evidence strength can be investigated independently, creating a structured three-way comparison within selective androgen-receptor research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eHow MK-2866, AC-262 and ACP-105 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, AC-262 and ACP-105 share their principal research connection through the androgen receptor. This receptor belongs to the nuclear-receptor superfamily and functions as a ligand-responsive transcriptional regulator. Interaction with suitable molecules can alter receptor conformation and subsequently influence co-regulatory interactions and expression of androgen-responsive genes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe scientific rationale behind selective androgen receptor modulators extends beyond simply identifying compounds capable of binding to the androgen receptor. Researchers have investigated whether structurally different non-steroidal ligands can generate different patterns of receptor activation and tissue-dependent experimental responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 provides the most established research reference within this set. Its comparatively developed evidence base allows Ostarine-associated observations to provide a useful benchmark when investigating other selective androgen-receptor compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 introduces a different pharmacological question because experimental research has associated AC-262,536 with partial-agonist behaviour. This makes the degree of receptor activation and resulting transcriptional response particularly relevant when comparing it with other androgen-receptor ligands.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eACP-105 provides a third selective androgen-receptor compound with its own preclinical research profile. Its inclusion broadens the comparison beyond two molecules and allows researchers to investigate another chemically distinct ligand within the same broad receptor system.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe three compounds should not be considered automatically synergistic. Sharing a molecular target does not establish that combining compounds enhances receptor activity or produces a predetermined biological result.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe research value instead lies in controlled comparison. MK-2866, AC-262 and ACP-105 can be examined using predefined receptor-associated, transcriptional or tissue-dependent endpoints while retaining separate controls.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis creates a structured framework for investigating how three chemically distinct selective androgen receptor modulators may differ despite belonging to the same broad pharmacological research category.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eMK-2866 (Ostarine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866, commonly known as Ostarine and associated with the developmental name Enobosarm, is a synthetic non-steroidal selective androgen receptor modulator with one of the more developed research histories among compounds within the SARM category.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts principal molecular target is the androgen receptor. Following interaction with an appropriate ligand, this nuclear receptor can influence transcription of androgen-responsive genes through changes in receptor conformation, co-regulatory interactions and subsequent cellular signalling.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe wider objective of SARM research has been to investigate whether non-steroidal androgen-receptor ligands can produce differing patterns of activity across experimental tissues. MK-2866 has consequently been investigated across receptor-level, tissue-associated and functional research settings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Selective Androgen Pathway Research Set, Ostarine provides an important reference point because its research history is more developed than those of AC-262 and ACP-105.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore establish MK-2866-specific experimental observations before comparing them with results obtained using the other two selective androgen-receptor compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis does not mean that MK-2866 represents a universal model for SARM behaviour. Different compounds can interact with the androgen receptor differently and generate different downstream responses according to molecular structure, concentration, receptor expression and cellular environment.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eNor does the existence of a larger evidence base establish every claim associated with Ostarine. Findings remain dependent upon experimental design, exposure, model and endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin this triple set, MK-2866 consequently provides the established SARM component against which the less extensively characterised AC-262 and ACP-105 can be compared, creating a broader laboratory framework for studying selective androgen-receptor pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eAC-262 (Accadrine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262, commonly known as Accadrine and identified scientifically as AC-262,536, is a synthetic non-steroidal selective androgen receptor modulator investigated through receptor-binding, transcriptional and preclinical research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eOne particularly interesting aspect of AC-262 research concerns its reported partial-agonist characteristics at the androgen receptor. A partial agonist interacts with a receptor but can produce a lower maximal response than a full agonist under comparable experimental conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis concept makes AC-262 useful for studying an important principle of receptor pharmacology: receptor binding and receptor activation are related but distinct measurements. Two ligands interacting with the same receptor do not necessarily produce identical downstream responses.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMolecular structure, ligand-induced receptor conformation, cellular co-regulators, receptor density and experimental environment can all contribute to the response observed after exposure to an androgen-receptor ligand.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Selective Androgen Pathway Research Set, AC-262 provides a particularly useful comparison with MK-2866. Ostarine possesses the more developed research history, whereas AC-262 introduces a compound associated with different receptor-activation characteristics.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eACP-105 then expands the comparison by introducing another chemically distinct non-steroidal selective androgen receptor modulator.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe evidence surrounding AC-262 remains smaller than the body of research available for Ostarine, meaning conclusions should remain specific to the experiments in which the compound has actually been investigated.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAC-262 should therefore not simply inherit findings associated with MK-2866 or other SARMs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts role within this triple set is to provide an independently characterised androgen-receptor ligand that can be examined alongside two other selective modulators. This allows researchers to investigate how different chemical structures and pharmacological characteristics may influence receptor-associated and transcriptional observations within a common experimental framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eACP-105 (Androxepen) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eACP-105, presented within the BioPlex research range as Androxepen, is a synthetic non-steroidal selective androgen receptor modulator investigated primarily through preclinical androgen-receptor research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts research history is less extensive than that of MK-2866 Ostarine, but ACP-105 has been examined as part of the broader scientific investigation into tissue-selective androgen-receptor pharmacology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAs with other SARMs, the central research interest concerns the relationship between molecular structure, androgen-receptor interaction and resulting biological activity across different experimental systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe androgen receptor does not respond identically to every ligand. Different molecules can influence receptor conformation and interactions with transcriptional co-regulators, creating the possibility of different downstream patterns of activity even when compounds share the same broad molecular target.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Selective Androgen Pathway Research Set, ACP-105 provides a third independent ligand for examining these principles.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMK-2866 provides the comparatively established reference compound. AC-262 introduces published research interest surrounding partial-agonist behaviour, while ACP-105 provides another structurally distinct non-steroidal androgen-receptor ligand with its own preclinical evidence profile.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can therefore investigate ACP-105 independently before comparing predefined experimental endpoints across all three compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe smaller evidence base surrounding ACP-105 also requires appropriate caution. Findings established for Ostarine should not automatically be transferred to ACP-105, and commercial descriptions should remain separate from conclusions supported by compound-specific research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts inclusion within the set consequently increases the breadth of the comparative research framework rather than simply increasing the number of compounds.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eTogether, ACP-105, AC-262 and MK-2866 provide three different non-steroidal molecules for controlled investigation of selective androgen-receptor signalling while preserving their individual chemical identities and evidence profiles.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related selective androgen receptor modulators from the BioPlex SARMs capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/mk-2688-ostarine-br-50x15mg\" title=\"MK-2866 Ostarine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView MK-2866 Ostarine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/products\/ac-262-accadrine-br-50x15mg\" title=\"AC-262 Accadrine | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eView AC-262 Accadrine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"ACP-105 Androxepen | Research SARM Capsules | BioPlex UK\"\u003e\u003cspan\u003eExplore ACP-105 Androxepen 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex SARMs guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs Research Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cspan\u003e\u003c\/span\u003e\u003cbr\u003e\n\u003c\/h3\u003e\n\u003ch3\u003e\u003cspan\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering Ostarine, AC-262, selective androgen-receptor signalling and comparative SARM research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/de\/blogs\/sarms-research-articles-bioplex-peptides-uk\/h1-science-research-studies-ac-262-vs-ostarine-mk-2866-androgen-receptor-research-compared\" title=\"AC-262 vs Ostarine MK-2866 | Androgen Receptor Research | BioPlex Peptides\"\u003e\u003cspan\u003eRead AC-262 vs Ostarine MK-2866: Androgen-Receptor Research Compared ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"MK-2866 AC-262 ACP-105 SARMs Research Guide | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs Research Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753870561664,"sku":null,"price":138.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/ACP-105_MK-2866_AC-262.png?v=1787435184"},{"product_id":"sr-9011-gw-0742","title":"SR-9011 + GW-0742","description":"\u003ch2\u003e\u003cspan\u003eSR-9011 (REV-ERB Agonist) + GW-0742 (Fitorine) | Metabolic Research UK\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch2\u003e\u003cspan\u003eEnergy Metabolism Research Set\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe BioPlex Energy Metabolism Research Set combines SR-9011 (REV-ERB Agonist) 50×15mg and GW-0742 (Fitorine) 50×15mg, bringing together two synthetic research compounds associated with distinct nuclear-receptor pathways involved in metabolic and cellular-energy research. The set contains one pot of each compound and provides a structured format for comparative laboratory investigation of REV-ERB-associated signalling alongside PPARδ-associated research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 is associated primarily with experimental investigation of REV-ERBα and REV-ERBβ. These nuclear receptors participate in transcriptional networks linking circadian regulation with metabolic processes, making them important targets in research examining the relationship between biological timing, gene expression and cellular metabolism.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eGW-0742 represents a separate molecular pathway. Presented within the BioPlex range as Fitorine, GW-0742 is associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ. Research involving this receptor has examined transcriptional pathways associated with lipid handling, fatty-acid metabolism and cellular-energy regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eNeither SR-9011 nor GW-0742 is scientifically classified as a selective androgen receptor modulator. Although compounds of this type may appear commercially alongside SARMs, their molecular targets and pharmacological classifications are different from androgen-receptor ligands such as RAD-140 or MK-2866.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe Energy Metabolism Research Set therefore creates a two-pathway laboratory research format rather than pairing compounds with an identical molecular target.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eEach compound remains individually identified, enabling researchers to investigate REV-ERB and PPARδ-associated pathways independently while comparing predefined metabolic and transcriptional endpoints within a controlled research framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eHow SR-9011 and GW-0742 Work Together\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 and GW-0742 provide an interesting comparative research pairing because each is associated with a different nuclear-receptor system connected with metabolic regulation. SR-9011 is associated with REV-ERB research, whereas GW-0742 is associated primarily with PPARδ.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eREV-ERBα and REV-ERBβ participate in the molecular machinery responsible for circadian transcriptional regulation. Circadian biology extends beyond the sleep-wake cycle and involves rhythmic changes in gene expression across numerous cellular and metabolic processes. This has made REV-ERB signalling an important area of experimental investigation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 has been used as a synthetic research compound within this field, allowing researchers to investigate relationships between REV-ERB-associated signalling, circadian transcription and predefined metabolic markers.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eGW-0742 provides a different research mechanism. PPARδ belongs to the nuclear-receptor superfamily and participates in transcriptional regulation of pathways involving lipid utilisation, fatty-acid metabolism and cellular-energy processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePlacing these two compounds within the same research set therefore allows researchers to consider two distinct transcriptional systems within a broader energy-metabolism framework.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe combination does not establish that SR-9011 and GW-0742 act synergistically. Nor does activity involving one receptor system demonstrate that the other pathway will respond in a particular manner. Cellular metabolism is controlled through interconnected regulatory networks, and experimental outcomes can vary according to model, concentration, receptor expression, exposure and methodology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThe research value instead comes from pathway comparison. SR-9011 provides the REV-ERB-associated component, while GW-0742 provides the PPARδ-associated component.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis creates a structured format for investigating different aspects of metabolic transcriptional regulation while maintaining appropriate compound-specific controls and scientifically accurate classification.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eSR-9011 (REV-ERB Agonist) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 is a synthetic research compound associated with experimental investigation of the nuclear receptors REV-ERBα and REV-ERBβ. It has been used within research examining circadian transcription, metabolic regulation and the molecular relationship between biological timing and cellular processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eREV-ERB receptors belong to the nuclear-receptor superfamily and participate in transcriptional networks forming part of the molecular circadian clock. Their regulatory activity connects circadian biology with broader areas of metabolism and gene expression.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis relationship has generated scientific interest in synthetic ligands capable of experimentally influencing REV-ERB-associated pathways. SR-9011 has consequently been investigated in experimental systems examining metabolic, transcriptional and circadian-associated endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eHowever, classification as a REV-ERB-associated research compound does not mean that every observed experimental response can automatically be attributed exclusively to REV-ERB signalling. Compound concentration, cellular environment, experimental model and potential off-target activity must be considered when interpreting findings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 is also not a SARM. Its principal research classification concerns REV-ERB-associated nuclear-receptor biology rather than selective modulation of the androgen receptor.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Energy Metabolism Research Set, SR-9011 provides the circadian and REV-ERB-associated component of the pairing.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis can be investigated independently before predefined observations are compared with the PPARδ-associated research profile of GW-0742.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eMaintaining this distinction is important because both compounds may be grouped commercially within broader research-compound categories despite having different molecular targets.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eSR-9011 therefore contributes a distinct transcriptional research pathway to the set, supporting comparative investigation of metabolic signalling without treating different classes of research compounds as pharmacologically interchangeable.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003eGW-0742 (Fitorine) 50×15mg\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eGW-0742, presented within the BioPlex research range as Fitorine, is a synthetic research compound associated primarily with peroxisome proliferator-activated receptor delta, commonly abbreviated PPARδ.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003ePPARδ belongs to the nuclear-receptor superfamily and functions as a transcriptional regulator. Research involving this receptor has examined gene-expression pathways associated with lipid handling, fatty-acid metabolism, cellular-energy regulation and related areas of metabolic biology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eGW-0742 has consequently been used experimentally as a pharmacological research tool for investigating PPARδ-associated signalling and determining how receptor modulation corresponds with changes in predefined molecular and cellular endpoints.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eIts molecular classification clearly distinguishes it from SR-9011. Although both compounds can be studied within the broad field of metabolic regulation, SR-9011 is associated with REV-ERB research whereas GW-0742 provides the PPARδ-focused component.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eGW-0742 is also not a selective androgen receptor modulator. Its inclusion within commercial research-compound ranges alongside SARMs should not be interpreted as evidence of androgen-receptor activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eWithin the Energy Metabolism Research Set, GW-0742 therefore provides a complementary but mechanistically distinct research pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eResearchers can investigate PPARδ-associated observations independently before comparing selected metabolic and transcriptional markers with those generated within SR-9011 experimental systems.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eThis approach preserves the pharmacological identity of each compound rather than assuming that shared relevance to metabolic research means identical biological activity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eConcentration, exposure, receptor expression, cellular environment and potential off-target effects remain important considerations when interpreting experimental findings.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eTogether with SR-9011, GW-0742 creates a two-compound framework for comparative investigation of nuclear-receptor pathways associated with metabolic and cellular-energy research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Compounds\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue exploring related metabolic and nuclear-receptor research compounds from the BioPlex capsule range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9011 REV-ERB Agonist | Metabolic Research Capsules | BioPlex UK\"\u003e\u003cspan\u003eView SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"GW-0742 Fitorine | PPARδ Research Compound | BioPlex UK\"\u003e\u003cspan\u003eView GW-0742 Fitorine 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9009 Stenabolic | Metabolic Research Capsules | BioPlex UK\"\u003e\u003cspan\u003eView SR-9009 Stenabolic 50×15mg Research Capsules ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore BioPlex Research Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"Complete SARMs UK Research Compound Guide 2026 | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs \u0026amp; Research Compounds UK | BioPlex Peptides\"\u003e\u003cspan\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003e\u003cspan\u003eView All BioPlex Research Products ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\u003cspan\u003e\u003cbr\u003eExplore Related Research Articles\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cspan\u003eContinue your research with BioPlex articles covering metabolic research compounds, nuclear-receptor signalling and the scientific classification of compounds sold alongside SARMs.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SR-9011 GW-0742 Research Compound Classification | BioPlex Peptides\"\u003e\u003cspan\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003e\u003cspan\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\u003cspan\u003e\u003cbr\u003eDisclaimer\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice\" title=\"Legal Notice | BioPlex Peptides UK\"\u003e\u003cspan\u003eFor research purposes only. Not for human consumption\u003c\/span\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlexPeptides.co.uk","offers":[{"title":"Default Title","offer_id":58756320592256,"sku":null,"price":89.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/SR-9011_GW-0742.png?v=1787440860"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/collections\/MaximumMyogenicResearchSet.png?v=1787402307","url":"https:\/\/bioplexpeptides.co.uk\/no\/collections\/sarms-research-sets-uk.oembed","provider":"BioPlexPeptides.co.uk","version":"1.0","type":"link"}